PMCID	SUBJECT_SCOPE_ID	S_START	S_END	SUBJECT_SCOPE	CONCEPT	IGNORANCE TYPE	C_START	C_END	CONCEPT_MENTION_ID
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	antiatherogenic	CHEBI_EXT	[14]	[29]	PMC1974834_T0
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	pregnancy	GO_BP_EXT	[42]	[51]	PMC1974834_T156
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	markers	CHEBI_EXT	[55]	[62]	PMC1974834_T1
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	markers	SO_EXT	[55]	[62]	PMC1974834_T442
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	endothelial	UBERON_EXT	[85]	[96]	PMC1974834_T472
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	endothelial activation	GO_BP_EXT	[85]	[107]	PMC1974834_T157
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	inflammation	GO_BP_EXT	[112]	[124]	PMC1974834_T158
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	antiatherogenic	CHEBI_EXT	[191]	[206]	PMC1974834_T2
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	cord	UBERON_EXT	[228]	[232]	PMC1974834_T473
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	blood	UBERON_EXT	[233]	[238]	PMC1974834_T474
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	biomarkers	CHEBI_EXT	[266]	[276]	PMC1974834_T3
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	biomarkers	CHEBI_EXT	[266]	[276]	PMC1974834_T443
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	endothelial	UBERON_EXT	[280]	[291]	PMC1974834_T475
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	endothelial cell	CL_EXT	[280]	[296]	PMC1974834_T150
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	endothelial cell activation	GO_BP_EXT	[280]	[307]	PMC1974834_T159
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	cell	CL_EXT	[292]	[296]	PMC1974834_T292
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	haemostasis	GO_BP_EXT	[309]	[320]	PMC1974834_T160
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	inflammation	GO_BP_EXT	[325]	[337]	PMC1974834_T161
PMC1974834	PMC1974834_2	[401]	[491]	['Setting\nObstetric outpatient clinic and maternity unit of a university hospital in Norway.']	Obstetric	UBERON_EXT	[409]	[418]	PMC1974834_T476
PMC1974834	PMC1974834_3	[493]	[624]	['Population\nNonsmoking pregnant women aged 21–38 years carrying a single fetus and with no previous pregnancy-related complications.']	pregnant	GO_BP_EXT	[515]	[523]	PMC1974834_T162
PMC1974834	PMC1974834_3	[493]	[624]	['Population\nNonsmoking pregnant women aged 21–38 years carrying a single fetus and with no previous pregnancy-related complications.']	women	NCBITAXON_EXT	[524]	[529]	PMC1974834_T318
PMC1974834	PMC1974834_3	[493]	[624]	['Population\nNonsmoking pregnant women aged 21–38 years carrying a single fetus and with no previous pregnancy-related complications.']	pregnancy	GO_BP_EXT	[592]	[601]	PMC1974834_T163
PMC1974834	PMC1974834_4	[626]	[792]	['Methods\nSubjects ( n = 290) were randomised to continue their usual diet or to adopt a diet low in saturated fat and cholesterol from gestational week 17–20 to birth.']	saturated fat	CHEBI_EXT	[725]	[738]	PMC1974834_T4
PMC1974834	PMC1974834_4	[626]	[792]	['Methods\nSubjects ( n = 290) were randomised to continue their usual diet or to adopt a diet low in saturated fat and cholesterol from gestational week 17–20 to birth.']	fat	CHEBI_EXT	[735]	[738]	PMC1974834_T477
PMC1974834	PMC1974834_4	[626]	[792]	['Methods\nSubjects ( n = 290) were randomised to continue their usual diet or to adopt a diet low in saturated fat and cholesterol from gestational week 17–20 to birth.']	cholesterol	CHEBI_EXT	[743]	[754]	PMC1974834_T5
PMC1974834	PMC1974834_4	[626]	[792]	['Methods\nSubjects ( n = 290) were randomised to continue their usual diet or to adopt a diet low in saturated fat and cholesterol from gestational week 17–20 to birth.']	gestational	GO_BP_EXT	[760]	[771]	PMC1974834_T164
PMC1974834	PMC1974834_4	[626]	[792]	['Methods\nSubjects ( n = 290) were randomised to continue their usual diet or to adopt a diet low in saturated fat and cholesterol from gestational week 17–20 to birth.']	birth	GO_BP_EXT	[786]	[791]	PMC1974834_T165
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	cellular	CL_EXT	[810]	[818]	PMC1974834_T151
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	cellular	CL_EXT	[810]	[818]	PMC1974834_T293
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	adhesion	GO_BP_EXT	[819]	[827]	PMC1974834_T166
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	molecules	CHEBI_EXT	[828]	[837]	PMC1974834_T6
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	high-sensitivity C-reactive protein	PR_EXT	[839]	[874]	PMC1974834_T343
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	protein	CHEBI_EXT	[867]	[874]	PMC1974834_T7
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	CRP	GO_MF_EXT	[876]	[879]	PMC1974834_T310
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	CRP	PR_EXT	[876]	[879]	PMC1974834_T344
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	haemostatic	GO_BP_EXT	[885]	[896]	PMC1974834_T167
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	markers	CHEBI_EXT	[897]	[904]	PMC1974834_T8
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	markers	SO_EXT	[897]	[904]	PMC1974834_T444
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	gestation	GO_BP_EXT	[937]	[946]	PMC1974834_T168
PMC1974834	PMC1974834_6	[990]	[1050]	['All the above, except CRP, were also measured in cord blood.']	CRP	PR_EXT	[1012]	[1015]	PMC1974834_T345
PMC1974834	PMC1974834_6	[990]	[1050]	['All the above, except CRP, were also measured in cord blood.']	cord	UBERON_EXT	[1039]	[1043]	PMC1974834_T478
PMC1974834	PMC1974834_6	[990]	[1050]	['All the above, except CRP, were also measured in cord blood.']	blood	UBERON_EXT	[1044]	[1049]	PMC1974834_T479
PMC1974834	PMC1974834_7	[1052]	[1139]	['Main outcome measures\nConcentrations of maternal and fetal biomarkers and maternal CRP.']	biomarkers	CHEBI_EXT	[1111]	[1121]	PMC1974834_T9
PMC1974834	PMC1974834_7	[1052]	[1139]	['Main outcome measures\nConcentrations of maternal and fetal biomarkers and maternal CRP.']	biomarkers	CHEBI_EXT	[1111]	[1121]	PMC1974834_T445
PMC1974834	PMC1974834_7	[1052]	[1139]	['Main outcome measures\nConcentrations of maternal and fetal biomarkers and maternal CRP.']	CRP	GO_MF_EXT	[1135]	[1138]	PMC1974834_T311
PMC1974834	PMC1974834_7	[1052]	[1139]	['Main outcome measures\nConcentrations of maternal and fetal biomarkers and maternal CRP.']	CRP	PR_EXT	[1135]	[1138]	PMC1974834_T346
PMC1974834	PMC1974834_8	[1141]	[1274]	['Results\nAll biomarkers except CRP levels increased significantly during the study period in both the intervention and control groups.']	biomarkers	CHEBI_EXT	[1153]	[1163]	PMC1974834_T10
PMC1974834	PMC1974834_8	[1141]	[1274]	['Results\nAll biomarkers except CRP levels increased significantly during the study period in both the intervention and control groups.']	biomarkers	CHEBI_EXT	[1153]	[1163]	PMC1974834_T446
PMC1974834	PMC1974834_8	[1141]	[1274]	['Results\nAll biomarkers except CRP levels increased significantly during the study period in both the intervention and control groups.']	CRP	GO_MF_EXT	[1171]	[1174]	PMC1974834_T312
PMC1974834	PMC1974834_8	[1141]	[1274]	['Results\nAll biomarkers except CRP levels increased significantly during the study period in both the intervention and control groups.']	CRP	PR_EXT	[1171]	[1174]	PMC1974834_T347
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	biomarkers	CHEBI_EXT	[1305]	[1315]	PMC1974834_T11
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	biomarkers	CHEBI_EXT	[1305]	[1315]	PMC1974834_T447
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	cord	UBERON_EXT	[1412]	[1416]	PMC1974834_T480
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	blood	UBERON_EXT	[1417]	[1422]	PMC1974834_T481
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	plasminogen activator antigen	PR_EXT	[1430]	[1459]	PMC1974834_T348
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	antigen	CHEBI_EXT	[1452]	[1459]	PMC1974834_T12
PMC1974834	PMC1974834_10	[1608]	[1769]	['Conclusion\nAn antiatherogenic diet in pregnancy did not significantly influence maternal or fetal blood concentrations of a range of biomarkers for inflammation.']	antiatherogenic	CHEBI_EXT	[1622]	[1637]	PMC1974834_T13
PMC1974834	PMC1974834_10	[1608]	[1769]	['Conclusion\nAn antiatherogenic diet in pregnancy did not significantly influence maternal or fetal blood concentrations of a range of biomarkers for inflammation.']	pregnancy	GO_BP_EXT	[1646]	[1655]	PMC1974834_T169
PMC1974834	PMC1974834_10	[1608]	[1769]	['Conclusion\nAn antiatherogenic diet in pregnancy did not significantly influence maternal or fetal blood concentrations of a range of biomarkers for inflammation.']	blood	UBERON_EXT	[1706]	[1711]	PMC1974834_T482
PMC1974834	PMC1974834_10	[1608]	[1769]	['Conclusion\nAn antiatherogenic diet in pregnancy did not significantly influence maternal or fetal blood concentrations of a range of biomarkers for inflammation.']	biomarkers	CHEBI_EXT	[1741]	[1751]	PMC1974834_T14
PMC1974834	PMC1974834_10	[1608]	[1769]	['Conclusion\nAn antiatherogenic diet in pregnancy did not significantly influence maternal or fetal blood concentrations of a range of biomarkers for inflammation.']	biomarkers	CHEBI_EXT	[1741]	[1751]	PMC1974834_T448
PMC1974834	PMC1974834_10	[1608]	[1769]	['Conclusion\nAn antiatherogenic diet in pregnancy did not significantly influence maternal or fetal blood concentrations of a range of biomarkers for inflammation.']	inflammation	GO_BP_EXT	[1756]	[1768]	PMC1974834_T170
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	cholesterol	CHEBI_EXT	[1813]	[1824]	PMC1974834_T15
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	lipid	CHEBI_EXT	[1851]	[1856]	PMC1974834_T16
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	delivery	GO_BP_EXT	[1877]	[1885]	PMC1974834_T171
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	gestation	GO_BP_EXT	[1909]	[1918]	PMC1974834_T172
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	inflammatory	GO_BP_EXT	[1967]	[1979]	PMC1974834_T173
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	responses	GO_BP_EXT	[1980]	[1989]	PMC1974834_T174
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	pregnancy	GO_BP_EXT	[1993]	[2002]	PMC1974834_T175
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	pregnancy	GO_BP_EXT	[2035]	[2044]	PMC1974834_T176
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	of ... pregnancy	GO_BP_EXT	[2088, 2097]	[2090, 2106]	PMC1974834_T177
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	delivery	GO_BP_EXT	[2136]	[2144]	PMC1974834_T178
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	coronary heart	UBERON_EXT	[2187]	[2201]	PMC1974834_T483
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	life	UBERON_EXT	[2219]	[2223]	PMC1974834_T484
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	uteroplacental	UBERON_EXT	[2255]	[2269]	PMC1974834_T485
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	circulation	UBERON_EXT	[2270]	[2281]	PMC1974834_T486
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	delivery	GO_BP_EXT	[2311]	[2319]	PMC1974834_T179
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	pregnancy	GO_BP_EXT	[2374]	[2383]	PMC1974834_T180
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	infant	UBERON_EXT	[2417]	[2423]	PMC1974834_T487
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	cardiovascular	UBERON_EXT	[2426]	[2440]	PMC1974834_T488
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	life	UBERON_EXT	[2455]	[2459]	PMC1974834_T489
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	childhood	UBERON_EXT	[2533]	[2542]	PMC1974834_T490
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	Cardiovascular	UBERON_EXT	[2567]	[2581]	PMC1974834_T491
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	Pregnancy	GO_BP_EXT	[2605]	[2614]	PMC1974834_T181
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	cholesterol	CHEBI_EXT	[2702]	[2713]	PMC1974834_T17
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	saturated	CHEBI_EXT	[2719]	[2728]	PMC1974834_T18
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	fat	CHEBI_EXT	[2729]	[2732]	PMC1974834_T19
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	fat	CHEBI_EXT	[2729]	[2732]	PMC1974834_T492
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	antiatherogenic	CHEBI_EXT	[2733]	[2748]	PMC1974834_T20
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	women	NCBITAXON_EXT	[2823]	[2828]	PMC1974834_T319
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	women	UBERON_EXT	[2823]	[2828]	PMC1974834_T493
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	cord	UBERON_EXT	[2842]	[2846]	PMC1974834_T494
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	neonatal	UBERON_EXT	[2851]	[2859]	PMC1974834_T495
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	lipid	CHEBI_EXT	[2860]	[2865]	PMC1974834_T21
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	pregnancy	GO_BP_EXT	[2889]	[2898]	PMC1974834_T182
PMC1974834	PMC1974834_13	[2908]	[3060]	['Maternal lipid concentrations were reduced in the intervention arm of the trial, while cord blood and neonatal lipids did not differ between the groups.']	lipid	CHEBI_EXT	[2917]	[2922]	PMC1974834_T22
PMC1974834	PMC1974834_13	[2908]	[3060]	['Maternal lipid concentrations were reduced in the intervention arm of the trial, while cord blood and neonatal lipids did not differ between the groups.']	cord	UBERON_EXT	[2995]	[2999]	PMC1974834_T496
PMC1974834	PMC1974834_13	[2908]	[3060]	['Maternal lipid concentrations were reduced in the intervention arm of the trial, while cord blood and neonatal lipids did not differ between the groups.']	blood	UBERON_EXT	[3000]	[3005]	PMC1974834_T497
PMC1974834	PMC1974834_13	[2908]	[3060]	['Maternal lipid concentrations were reduced in the intervention arm of the trial, while cord blood and neonatal lipids did not differ between the groups.']	neonatal	UBERON_EXT	[3010]	[3018]	PMC1974834_T498
PMC1974834	PMC1974834_13	[2908]	[3060]	['Maternal lipid concentrations were reduced in the intervention arm of the trial, while cord blood and neonatal lipids did not differ between the groups.']	lipids	CHEBI_EXT	[3019]	[3025]	PMC1974834_T23
PMC1974834	PMC1974834_15	[3103]	[3259]	['However, there was a marked reduction in the incidence of preterm delivery (a live birth prior to 37 complete weeks of gestation) in the intervention group.']	delivery	GO_BP_EXT	[3169]	[3177]	PMC1974834_T183
PMC1974834	PMC1974834_15	[3103]	[3259]	['However, there was a marked reduction in the incidence of preterm delivery (a live birth prior to 37 complete weeks of gestation) in the intervention group.']	birth	GO_BP_EXT	[3186]	[3191]	PMC1974834_T184
PMC1974834	PMC1974834_15	[3103]	[3259]	['However, there was a marked reduction in the incidence of preterm delivery (a live birth prior to 37 complete weeks of gestation) in the intervention group.']	gestation	GO_BP_EXT	[3222]	[3231]	PMC1974834_T185
PMC1974834	PMC1974834_16	[3260]	[3353]	['Gestational age was based on the ultrasound examination performed at week 17–18 of gestation.']	Gestational	GO_BP_EXT	[3260]	[3271]	PMC1974834_T186
PMC1974834	PMC1974834_16	[3260]	[3353]	['Gestational age was based on the ultrasound examination performed at week 17–18 of gestation.']	gestation	GO_BP_EXT	[3343]	[3352]	PMC1974834_T187
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	pregnancy	GO_BP_EXT	[3446]	[3455]	PMC1974834_T188
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	Inflammatory	GO_BP_EXT	[3472]	[3484]	PMC1974834_T189
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	atherogenic	GO_BP_EXT	[3512]	[3523]	PMC1974834_T190
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	pregnancy	GO_BP_EXT	[3556]	[3565]	PMC1974834_T191
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	delivery	GO_BP_EXT	[3598]	[3606]	PMC1974834_T192
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	blood	UBERON_EXT	[3658]	[3663]	PMC1974834_T499
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	adhesion	GO_BP_EXT	[3690]	[3698]	PMC1974834_T193
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	molecules	CHEBI_EXT	[3699]	[3708]	PMC1974834_T24
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	molecules	PR_EXT	[3699]	[3708]	PMC1974834_T349
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	sCAMs	PR_EXT	[3710]	[3715]	PMC1974834_T350
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	markers	CHEBI_EXT	[3718]	[3725]	PMC1974834_T25
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	inflammation	GO_BP_EXT	[3729]	[3741]	PMC1974834_T194
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	endothelial	UBERON_EXT	[3746]	[3757]	PMC1974834_T500
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	vascular	UBERON_EXT	[3778]	[3786]	PMC1974834_T501
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	vascular adhesion molecule	PR_EXT	[3778]	[3804]	PMC1974834_T351
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	adhesion	GO_BP_EXT	[3787]	[3795]	PMC1974834_T195
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	molecule	CHEBI_EXT	[3796]	[3804]	PMC1974834_T26
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	VCAM-1	PR_EXT	[3806]	[3812]	PMC1974834_T352
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	1	GO_CC_EXT	[3811]	[3812]	PMC1974834_T294
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	intercellular	CL_EXT	[3818]	[3831]	PMC1974834_T152
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	intercellular	GO_CC_EXT	[3818]	[3831]	PMC1974834_T295
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	intercellular adhesion molecule	PR_EXT	[3818]	[3849]	PMC1974834_T353
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	adhesion	GO_BP_EXT	[3832]	[3840]	PMC1974834_T196
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	molecule	CHEBI_EXT	[3841]	[3849]	PMC1974834_T27
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	ICAM-1	GO_CC_EXT	[3851]	[3857]	PMC1974834_T296
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	ICAM-1	PR_EXT	[3851]	[3857]	PMC1974834_T354
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	high-sensitivity C-reactive protein	PR_EXT	[3949]	[3984]	PMC1974834_T355
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	C-reactive	CHEBI_EXT	[3966]	[3976]	PMC1974834_T28
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	protein	CHEBI_EXT	[3977]	[3984]	PMC1974834_T29
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	CRP	GO_MF_EXT	[3986]	[3989]	PMC1974834_T313
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	CRP	PR_EXT	[3986]	[3989]	PMC1974834_T356
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	marker	CHEBI_EXT	[4023]	[4029]	PMC1974834_T30
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	cardiovascular	UBERON_EXT	[4034]	[4048]	PMC1974834_T502
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	women	NCBITAXON_EXT	[4102]	[4107]	PMC1974834_T320
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	women	UBERON_EXT	[4102]	[4107]	PMC1974834_T503
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	growth	GO_BP_EXT	[4156]	[4162]	PMC1974834_T197
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	women	NCBITAXON_EXT	[4189]	[4194]	PMC1974834_T321
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	women	UBERON_EXT	[4189]	[4194]	PMC1974834_T504
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	pregnancies	GO_BP_EXT	[4214]	[4225]	PMC1974834_T198
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	markers	CHEBI_EXT	[4244]	[4251]	PMC1974834_T31
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	markers	SO_EXT	[4244]	[4251]	PMC1974834_T449
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	prothrombotic	GO_BP_EXT	[4255]	[4268]	PMC1974834_T199
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	von Willebrand’s factor	PR_EXT	[4283]	[4306]	PMC1974834_T357
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	vWF	PR_EXT	[4308]	[4311]	PMC1974834_T358
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	markers	CHEBI_EXT	[4317]	[4324]	PMC1974834_T32
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	markers	SO_EXT	[4317]	[4324]	PMC1974834_T450
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	fibrinolysis	GO_BP_EXT	[4337]	[4349]	PMC1974834_T200
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	plasminogen activator inhibitor type 1	PR_EXT	[4360]	[4398]	PMC1974834_T359
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	inhibitor	CHEBI_EXT	[4382]	[4391]	PMC1974834_T33
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	PAI-1	PR_EXT	[4400]	[4405]	PMC1974834_T360
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	PAI type 2	PR_EXT	[4417]	[4427]	PMC1974834_T361
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	PAI-2 antigen	PR_EXT	[4429]	[4442]	PMC1974834_T362
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	antigen	CHEBI_EXT	[4435]	[4442]	PMC1974834_T34
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	tissue	UBERON_EXT	[4448]	[4454]	PMC1974834_T505
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	tissue plasminogen activator antigen	PR_EXT	[4448]	[4484]	PMC1974834_T363
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	antigen	CHEBI_EXT	[4477]	[4484]	PMC1974834_T35
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	tPAag	PR_EXT	[4486]	[4491]	PMC1974834_T364
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	markers	CHEBI_EXT	[4529]	[4536]	PMC1974834_T36
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	cardiovascular	UBERON_EXT	[4540]	[4554]	PMC1974834_T506
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	pregnancy	GO_BP_EXT	[4613]	[4622]	PMC1974834_T201
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	sCAMs	PR_EXT	[4731]	[4736]	PMC1974834_T365
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	cardiovascular	UBERON_EXT	[4753]	[4767]	PMC1974834_T507
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	pregnancy	GO_BP_EXT	[4850]	[4859]	PMC1974834_T202
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	antiatherogenic	CHEBI_EXT	[4938]	[4953]	PMC1974834_T37
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	cord	UBERON_EXT	[4982]	[4986]	PMC1974834_T508
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	blood	UBERON_EXT	[4987]	[4992]	PMC1974834_T509
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	sCAMs	PR_EXT	[5012]	[5017]	PMC1974834_T366
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	markers	CHEBI_EXT	[5019]	[5026]	PMC1974834_T38
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	markers	SO_EXT	[5019]	[5026]	PMC1974834_T451
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	thrombosis	GO_BP_EXT	[5030]	[5040]	PMC1974834_T203
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	fibrinolysis	GO_BP_EXT	[5045]	[5057]	PMC1974834_T204
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	CRP	PR_EXT	[5101]	[5104]	PMC1974834_T367
PMC1974834	PMC1974834_19	[5107]	[5407]	['Methods\nThe trial has been described in detail previously.9In brief, 290 healthy, nonsmoking, pregnant white European women aged 21–38 years, without a previous or current pregnancy complication and carrying a single healthy fetus, were randomised to follow their usual diet or the intervention diet.']	pregnant	GO_BP_EXT	[5201]	[5209]	PMC1974834_T205
PMC1974834	PMC1974834_19	[5107]	[5407]	['Methods\nThe trial has been described in detail previously.9In brief, 290 healthy, nonsmoking, pregnant white European women aged 21–38 years, without a previous or current pregnancy complication and carrying a single healthy fetus, were randomised to follow their usual diet or the intervention diet.']	women	NCBITAXON_EXT	[5225]	[5230]	PMC1974834_T322
PMC1974834	PMC1974834_19	[5107]	[5407]	['Methods\nThe trial has been described in detail previously.9In brief, 290 healthy, nonsmoking, pregnant white European women aged 21–38 years, without a previous or current pregnancy complication and carrying a single healthy fetus, were randomised to follow their usual diet or the intervention diet.']	women	UBERON_EXT	[5225]	[5230]	PMC1974834_T510
PMC1974834	PMC1974834_19	[5107]	[5407]	['Methods\nThe trial has been described in detail previously.9In brief, 290 healthy, nonsmoking, pregnant white European women aged 21–38 years, without a previous or current pregnancy complication and carrying a single healthy fetus, were randomised to follow their usual diet or the intervention diet.']	pregnancy	GO_BP_EXT	[5279]	[5288]	PMC1974834_T206
PMC1974834	PMC1974834_21	[5512]	[5774]	['who had no contact with the pregnant women (as described previously).9Sealed opaque envelopes consecutively numbered and containing the randomisation number and code (control or intervention) were given to the dietician responsible for giving the dietary advice.']	pregnant	GO_BP_EXT	[5540]	[5548]	PMC1974834_T207
PMC1974834	PMC1974834_21	[5512]	[5774]	['who had no contact with the pregnant women (as described previously).9Sealed opaque envelopes consecutively numbered and containing the randomisation number and code (control or intervention) were given to the dietician responsible for giving the dietary advice.']	women	NCBITAXON_EXT	[5549]	[5554]	PMC1974834_T323
PMC1974834	PMC1974834_22	[5775]	[5986]	['Thereafter, each screened and eligible woman was allocated the next available number by the dietician who opened the envelope to determine whether the woman was to follow the usual diet or the intervention diet.']	woman	NCBITAXON_EXT	[5814]	[5819]	PMC1974834_T324
PMC1974834	PMC1974834_22	[5775]	[5986]	['Thereafter, each screened and eligible woman was allocated the next available number by the dietician who opened the envelope to determine whether the woman was to follow the usual diet or the intervention diet.']	woman	UBERON_EXT	[5814]	[5819]	PMC1974834_T511
PMC1974834	PMC1974834_22	[5775]	[5986]	['Thereafter, each screened and eligible woman was allocated the next available number by the dietician who opened the envelope to determine whether the woman was to follow the usual diet or the intervention diet.']	woman	NCBITAXON_EXT	[5926]	[5931]	PMC1974834_T325
PMC1974834	PMC1974834_22	[5775]	[5986]	['Thereafter, each screened and eligible woman was allocated the next available number by the dietician who opened the envelope to determine whether the woman was to follow the usual diet or the intervention diet.']	woman	UBERON_EXT	[5926]	[5931]	PMC1974834_T512
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	cholesterol	CHEBI_EXT	[6032]	[6043]	PMC1974834_T39
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	saturated fat	CHEBI_EXT	[6072]	[6085]	PMC1974834_T40
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	fat	CHEBI_EXT	[6082]	[6085]	PMC1974834_T513
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	saturated fat	CHEBI_EXT	[6099]	[6112]	PMC1974834_T41
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	fat	CHEBI_EXT	[6109]	[6112]	PMC1974834_T514
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	monounsaturated	CHEBI_EXT	[6118]	[6133]	PMC1974834_T42
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	monounsaturated	SO_EXT	[6118]	[6133]	PMC1974834_T452
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	fat	CHEBI_EXT	[6154]	[6157]	PMC1974834_T43
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	fat	CHEBI_EXT	[6154]	[6157]	PMC1974834_T515
PMC1974834	PMC1974834_24	[6159]	[6402]	['Women in the intervention group ( n = 141) were advised to consume fish, low-fat meats, oils and low-fat dairy products instead of full-fat dairy products and meats, and to increase their intake of whole grains, fruits, vegetables and legumes.']	Women	NCBITAXON_EXT	[6159]	[6164]	PMC1974834_T326
PMC1974834	PMC1974834_24	[6159]	[6402]	['Women in the intervention group ( n = 141) were advised to consume fish, low-fat meats, oils and low-fat dairy products instead of full-fat dairy products and meats, and to increase their intake of whole grains, fruits, vegetables and legumes.']	Women	UBERON_EXT	[6159]	[6164]	PMC1974834_T516
PMC1974834	PMC1974834_24	[6159]	[6402]	['Women in the intervention group ( n = 141) were advised to consume fish, low-fat meats, oils and low-fat dairy products instead of full-fat dairy products and meats, and to increase their intake of whole grains, fruits, vegetables and legumes.']	consume	GO_BP_EXT	[6218]	[6225]	PMC1974834_T208
PMC1974834	PMC1974834_24	[6159]	[6402]	['Women in the intervention group ( n = 141) were advised to consume fish, low-fat meats, oils and low-fat dairy products instead of full-fat dairy products and meats, and to increase their intake of whole grains, fruits, vegetables and legumes.']	fat	CHEBI_EXT	[6236]	[6239]	PMC1974834_T44
PMC1974834	PMC1974834_24	[6159]	[6402]	['Women in the intervention group ( n = 141) were advised to consume fish, low-fat meats, oils and low-fat dairy products instead of full-fat dairy products and meats, and to increase their intake of whole grains, fruits, vegetables and legumes.']	fat	CHEBI_EXT	[6260]	[6263]	PMC1974834_T45
PMC1974834	PMC1974834_24	[6159]	[6402]	['Women in the intervention group ( n = 141) were advised to consume fish, low-fat meats, oils and low-fat dairy products instead of full-fat dairy products and meats, and to increase their intake of whole grains, fruits, vegetables and legumes.']	fat	CHEBI_EXT	[6295]	[6298]	PMC1974834_T46
PMC1974834	PMC1974834_24	[6159]	[6402]	['Women in the intervention group ( n = 141) were advised to consume fish, low-fat meats, oils and low-fat dairy products instead of full-fat dairy products and meats, and to increase their intake of whole grains, fruits, vegetables and legumes.']	fat	CHEBI_EXT	[6295]	[6298]	PMC1974834_T517
PMC1974834	PMC1974834_24	[6159]	[6402]	['Women in the intervention group ( n = 141) were advised to consume fish, low-fat meats, oils and low-fat dairy products instead of full-fat dairy products and meats, and to increase their intake of whole grains, fruits, vegetables and legumes.']	legumes	CHEBI_EXT	[6394]	[6401]	PMC1974834_T47
PMC1974834	PMC1974834_25	[6403]	[6548]	['Both the intervention and control groups followed the same schedule of blood sampling, physician and dietician visits and assessments (Figure 1).']	blood	UBERON_EXT	[6474]	[6479]	PMC1974834_T518
PMC1974834	PMC1974834_26	[6549]	[6631]	['Usual antenatal care was provided by the woman’s general physician and/or midwife.']	antenatal	GO_BP_EXT	[6555]	[6564]	PMC1974834_T209
PMC1974834	PMC1974834_26	[6549]	[6631]	['Usual antenatal care was provided by the woman’s general physician and/or midwife.']	woman	NCBITAXON_EXT	[6590]	[6595]	PMC1974834_T327
PMC1974834	PMC1974834_28	[6772]	[6942]	['The physicians and midwives caring for the women, the specialist physician (J.K.) and all laboratory and other personnel were blinded with regard to treatment assignment.']	women	NCBITAXON_EXT	[6815]	[6820]	PMC1974834_T328
PMC1974834	PMC1974834_28	[6772]	[6942]	['The physicians and midwives caring for the women, the specialist physician (J.K.) and all laboratory and other personnel were blinded with regard to treatment assignment.']	women	UBERON_EXT	[6815]	[6820]	PMC1974834_T519
PMC1974834	PMC1974834_31	[7115]	[7236]	['To assess dietary compliance, the weighed dietary intake was recorded on a predetermined day weekly throughout pregnancy.']	pregnancy	GO_BP_EXT	[7226]	[7235]	PMC1974834_T210
PMC1974834	PMC1974834_32	[7237]	[7330]	['The women were instructed in the cumulative weighing technique using a digital dietary scale.']	women	NCBITAXON_EXT	[7241]	[7246]	PMC1974834_T329
PMC1974834	PMC1974834_32	[7237]	[7330]	['The women were instructed in the cumulative weighing technique using a digital dietary scale.']	women	UBERON_EXT	[7241]	[7246]	PMC1974834_T520
PMC1974834	PMC1974834_33	[7331]	[7390]	['All food and beverages consumed were described and weighed.']	food	CHEBI_EXT	[7335]	[7339]	PMC1974834_T48
PMC1974834	PMC1974834_33	[7331]	[7390]	['All food and beverages consumed were described and weighed.']	beverages	CHEBI_EXT	[7344]	[7353]	PMC1974834_T49
PMC1974834	PMC1974834_33	[7331]	[7390]	['All food and beverages consumed were described and weighed.']	consumed	GO_BP_EXT	[7354]	[7362]	PMC1974834_T211
PMC1974834	PMC1974834_34	[7391]	[7645]	['The dietary records were entered into the database by certified personnel and scored using the software program Beregn developed by the Department of Nutrition, University of Oslo, and based on the Norwegian food table (1995; National Nutrition Council).']	food	CHEBI_EXT	[7599]	[7603]	PMC1974834_T50
PMC1974834	PMC1974834_35	[7646]	[7725]	['Foods or recipes that were not part of the programme were calculated and added.']	Foods	CHEBI_EXT	[7646]	[7651]	PMC1974834_T51
PMC1974834	PMC1974834_36	[7726]	[7788]	['Vitamin or iron supplements were not included in the analyses.']	Vitamin	CHEBI_EXT	[7726]	[7733]	PMC1974834_T52
PMC1974834	PMC1974834_36	[7726]	[7788]	['Vitamin or iron supplements were not included in the analyses.']	iron	CHEBI_EXT	[7737]	[7741]	PMC1974834_T53
PMC1974834	PMC1974834_37	[7790]	[7967]	['Laboratory methods\nBlood samples for measuring the risk markers (hereinafter referred to as biomarkers) were obtained at each visit after an overnight fast of at least 10 hours.']	Blood	UBERON_EXT	[7809]	[7814]	PMC1974834_T521
PMC1974834	PMC1974834_37	[7790]	[7967]	['Laboratory methods\nBlood samples for measuring the risk markers (hereinafter referred to as biomarkers) were obtained at each visit after an overnight fast of at least 10 hours.']	markers	CHEBI_EXT	[7846]	[7853]	PMC1974834_T54
PMC1974834	PMC1974834_37	[7790]	[7967]	['Laboratory methods\nBlood samples for measuring the risk markers (hereinafter referred to as biomarkers) were obtained at each visit after an overnight fast of at least 10 hours.']	markers	SO_EXT	[7846]	[7853]	PMC1974834_T453
PMC1974834	PMC1974834_37	[7790]	[7967]	['Laboratory methods\nBlood samples for measuring the risk markers (hereinafter referred to as biomarkers) were obtained at each visit after an overnight fast of at least 10 hours.']	biomarkers	CHEBI_EXT	[7882]	[7892]	PMC1974834_T55
PMC1974834	PMC1974834_37	[7790]	[7967]	['Laboratory methods\nBlood samples for measuring the risk markers (hereinafter referred to as biomarkers) were obtained at each visit after an overnight fast of at least 10 hours.']	biomarkers	CHEBI_EXT	[7882]	[7892]	PMC1974834_T454
PMC1974834	PMC1974834_38	[7968]	[8074]	['VCAM-1, ICAM-1 and E-selectin were measured at 17–20 weeks of gestation (baseline) and at weeks 30 and 36.']	VCAM-1	PR_EXT	[7968]	[7974]	PMC1974834_T368
PMC1974834	PMC1974834_38	[7968]	[8074]	['VCAM-1, ICAM-1 and E-selectin were measured at 17–20 weeks of gestation (baseline) and at weeks 30 and 36.']	ICAM-1	PR_EXT	[7976]	[7982]	PMC1974834_T369
PMC1974834	PMC1974834_38	[7968]	[8074]	['VCAM-1, ICAM-1 and E-selectin were measured at 17–20 weeks of gestation (baseline) and at weeks 30 and 36.']	-1	GO_CC_EXT	[7980]	[7982]	PMC1974834_T297
PMC1974834	PMC1974834_38	[7968]	[8074]	['VCAM-1, ICAM-1 and E-selectin were measured at 17–20 weeks of gestation (baseline) and at weeks 30 and 36.']	E-selectin	PR_EXT	[7987]	[7997]	PMC1974834_T370
PMC1974834	PMC1974834_38	[7968]	[8074]	['VCAM-1, ICAM-1 and E-selectin were measured at 17–20 weeks of gestation (baseline) and at weeks 30 and 36.']	gestation	GO_BP_EXT	[8030]	[8039]	PMC1974834_T212
PMC1974834	PMC1974834_39	[8075]	[8148]	['High-sensitivity CRP was measured at baseline and at weeks 24, 30 and 36.']	High-sensitivity	PR_EXT	[8075]	[8091]	PMC1974834_T371
PMC1974834	PMC1974834_39	[8075]	[8148]	['High-sensitivity CRP was measured at baseline and at weeks 24, 30 and 36.']	CRP	CHEBI_EXT	[8092]	[8095]	PMC1974834_T56
PMC1974834	PMC1974834_39	[8075]	[8148]	['High-sensitivity CRP was measured at baseline and at weeks 24, 30 and 36.']	CRP	PR_EXT	[8092]	[8095]	PMC1974834_T372
PMC1974834	PMC1974834_40	[8149]	[8215]	['PAI-1, PAI-2, tPAag and vWF were measured at baseline and week 36.']	PAI-1	PR_EXT	[8149]	[8154]	PMC1974834_T373
PMC1974834	PMC1974834_40	[8149]	[8215]	['PAI-1, PAI-2, tPAag and vWF were measured at baseline and week 36.']	PAI-2	PR_EXT	[8156]	[8161]	PMC1974834_T374
PMC1974834	PMC1974834_40	[8149]	[8215]	['PAI-1, PAI-2, tPAag and vWF were measured at baseline and week 36.']	tPAag	PR_EXT	[8163]	[8168]	PMC1974834_T375
PMC1974834	PMC1974834_40	[8149]	[8215]	['PAI-1, PAI-2, tPAag and vWF were measured at baseline and week 36.']	vWF	PR_EXT	[8173]	[8176]	PMC1974834_T376
PMC1974834	PMC1974834_41	[8216]	[8276]	['All the above, except CRP, were also measured in cord blood.']	CRP	PR_EXT	[8238]	[8241]	PMC1974834_T377
PMC1974834	PMC1974834_41	[8216]	[8276]	['All the above, except CRP, were also measured in cord blood.']	cord	UBERON_EXT	[8265]	[8269]	PMC1974834_T522
PMC1974834	PMC1974834_41	[8216]	[8276]	['All the above, except CRP, were also measured in cord blood.']	blood	UBERON_EXT	[8270]	[8275]	PMC1974834_T523
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	Serum	UBERON_EXT	[8277]	[8282]	PMC1974834_T524
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	VCAM-1	PR_EXT	[8337]	[8343]	PMC1974834_T378
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	-1	GO_CC_EXT	[8341]	[8343]	PMC1974834_T298
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	ICAM-1	GO_CC_EXT	[8345]	[8351]	PMC1974834_T299
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	ICAM-1	PR_EXT	[8345]	[8351]	PMC1974834_T379
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	E-selectin	PR_EXT	[8353]	[8363]	PMC1974834_T380
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	CRP	GO_MF_EXT	[8368]	[8371]	PMC1974834_T314
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	CRP	PR_EXT	[8368]	[8371]	PMC1974834_T381
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	Blood	UBERON_EXT	[8373]	[8378]	PMC1974834_T525
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	platelet	CL_EXT	[8402]	[8410]	PMC1974834_T153
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	plasma	UBERON_EXT	[8425]	[8431]	PMC1974834_T526
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	cord	UBERON_EXT	[8537]	[8541]	PMC1974834_T527
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	blood	UBERON_EXT	[8542]	[8547]	PMC1974834_T528
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	PAI-1	PR_EXT	[8578]	[8583]	PMC1974834_T382
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	PAI-2	PR_EXT	[8585]	[8590]	PMC1974834_T383
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	tPAag	PR_EXT	[8592]	[8597]	PMC1974834_T384
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	vWF	PR_EXT	[8602]	[8605]	PMC1974834_T385
PMC1974834	PMC1974834_46	[8708]	[8925]	['sCAMs were analysed with kits provided by R&D Systems Europe, Abingdon, Oxon, UK, and the individual CAMs had the following coefficients of inter-assay variation (CV): VCAM-1, 5.2%; ICAM-1, 4.8%; and E-selectin, 5.3%.']	VCAM-1	PR_EXT	[8876]	[8882]	PMC1974834_T386
PMC1974834	PMC1974834_46	[8708]	[8925]	['sCAMs were analysed with kits provided by R&D Systems Europe, Abingdon, Oxon, UK, and the individual CAMs had the following coefficients of inter-assay variation (CV): VCAM-1, 5.2%; ICAM-1, 4.8%; and E-selectin, 5.3%.']	ICAM-1	GO_CC_EXT	[8890]	[8896]	PMC1974834_T300
PMC1974834	PMC1974834_46	[8708]	[8925]	['sCAMs were analysed with kits provided by R&D Systems Europe, Abingdon, Oxon, UK, and the individual CAMs had the following coefficients of inter-assay variation (CV): VCAM-1, 5.2%; ICAM-1, 4.8%; and E-selectin, 5.3%.']	ICAM-1	PR_EXT	[8890]	[8896]	PMC1974834_T387
PMC1974834	PMC1974834_46	[8708]	[8925]	['sCAMs were analysed with kits provided by R&D Systems Europe, Abingdon, Oxon, UK, and the individual CAMs had the following coefficients of inter-assay variation (CV): VCAM-1, 5.2%; ICAM-1, 4.8%; and E-selectin, 5.3%.']	E-selectin	PR_EXT	[8908]	[8918]	PMC1974834_T388
PMC1974834	PMC1974834_46	[8708]	[8925]	['sCAMs were analysed with kits provided by R&D Systems Europe, Abingdon, Oxon, UK, and the individual CAMs had the following coefficients of inter-assay variation (CV): VCAM-1, 5.2%; ICAM-1, 4.8%; and E-selectin, 5.3%.']	-selectin	GO_CC_EXT	[8909]	[8918]	PMC1974834_T301
PMC1974834	PMC1974834_47	[8926]	[9022]	['High-sensitivity CRP was measured by means of the Roche Modular electrochemoluminescence method.']	CRP	PR_EXT	[8943]	[8946]	PMC1974834_T389
PMC1974834	PMC1974834_49	[9111]	[9435]	['Commercial methods were also used for analyses of the haemostatic parameters as follows: Spectrolyse/pL PAI-1 (Biopool AB, Umeå, Sweden; CV 4.2%), Imubind PAI-2 (American Diagnostica Inc., Greenwich, CT, USA; CV 6.3%), TintElize tPAag (Biopool AB; CV 3.5%) and Asserachrom vWF (Stago Diagnostica, Asnieres, France; CV 8.0%).']	haemostatic	GO_BP_EXT	[9165]	[9176]	PMC1974834_T213
PMC1974834	PMC1974834_49	[9111]	[9435]	['Commercial methods were also used for analyses of the haemostatic parameters as follows: Spectrolyse/pL PAI-1 (Biopool AB, Umeå, Sweden; CV 4.2%), Imubind PAI-2 (American Diagnostica Inc., Greenwich, CT, USA; CV 6.3%), TintElize tPAag (Biopool AB; CV 3.5%) and Asserachrom vWF (Stago Diagnostica, Asnieres, France; CV 8.0%).']	PAI-1	PR_EXT	[9215]	[9220]	PMC1974834_T390
PMC1974834	PMC1974834_49	[9111]	[9435]	['Commercial methods were also used for analyses of the haemostatic parameters as follows: Spectrolyse/pL PAI-1 (Biopool AB, Umeå, Sweden; CV 4.2%), Imubind PAI-2 (American Diagnostica Inc., Greenwich, CT, USA; CV 6.3%), TintElize tPAag (Biopool AB; CV 3.5%) and Asserachrom vWF (Stago Diagnostica, Asnieres, France; CV 8.0%).']	PAI-2	PR_EXT	[9266]	[9271]	PMC1974834_T391
PMC1974834	PMC1974834_49	[9111]	[9435]	['Commercial methods were also used for analyses of the haemostatic parameters as follows: Spectrolyse/pL PAI-1 (Biopool AB, Umeå, Sweden; CV 4.2%), Imubind PAI-2 (American Diagnostica Inc., Greenwich, CT, USA; CV 6.3%), TintElize tPAag (Biopool AB; CV 3.5%) and Asserachrom vWF (Stago Diagnostica, Asnieres, France; CV 8.0%).']	vWF	PR_EXT	[9384]	[9387]	PMC1974834_T392
PMC1974834	PMC1974834_50	[9436]	[9543]	['Fatty acid measurements were carried out in serum frozen immediately after venesection and stored at −70°C.']	Fatty	CHEBI_EXT	[9436]	[9441]	PMC1974834_T529
PMC1974834	PMC1974834_50	[9436]	[9543]	['Fatty acid measurements were carried out in serum frozen immediately after venesection and stored at −70°C.']	Fatty acid	CHEBI_EXT	[9436]	[9446]	PMC1974834_T57
PMC1974834	PMC1974834_50	[9436]	[9543]	['Fatty acid measurements were carried out in serum frozen immediately after venesection and stored at −70°C.']	serum	UBERON_EXT	[9480]	[9485]	PMC1974834_T530
PMC1974834	PMC1974834_52	[9631]	[9750]	['Serum total fatty acid profiles were determined at baseline and at gestational week 36 by extracting lipids from serum.']	Serum	UBERON_EXT	[9631]	[9636]	PMC1974834_T531
PMC1974834	PMC1974834_52	[9631]	[9750]	['Serum total fatty acid profiles were determined at baseline and at gestational week 36 by extracting lipids from serum.']	fatty	CHEBI_EXT	[9643]	[9648]	PMC1974834_T532
PMC1974834	PMC1974834_52	[9631]	[9750]	['Serum total fatty acid profiles were determined at baseline and at gestational week 36 by extracting lipids from serum.']	fatty acid	CHEBI_EXT	[9643]	[9653]	PMC1974834_T58
PMC1974834	PMC1974834_52	[9631]	[9750]	['Serum total fatty acid profiles were determined at baseline and at gestational week 36 by extracting lipids from serum.']	gestational	GO_BP_EXT	[9698]	[9709]	PMC1974834_T214
PMC1974834	PMC1974834_52	[9631]	[9750]	['Serum total fatty acid profiles were determined at baseline and at gestational week 36 by extracting lipids from serum.']	lipids	CHEBI_EXT	[9732]	[9738]	PMC1974834_T59
PMC1974834	PMC1974834_52	[9631]	[9750]	['Serum total fatty acid profiles were determined at baseline and at gestational week 36 by extracting lipids from serum.']	serum	UBERON_EXT	[9744]	[9749]	PMC1974834_T533
PMC1974834	PMC1974834_53	[9751]	[9866]	['After transesterification, fatty acid methyl esters were separated by means of capillary gas liquid chromatography.']	transesterification	GO_BP_EXT	[9757]	[9776]	PMC1974834_T215
PMC1974834	PMC1974834_53	[9751]	[9866]	['After transesterification, fatty acid methyl esters were separated by means of capillary gas liquid chromatography.']	fatty	CHEBI_EXT	[9778]	[9783]	PMC1974834_T534
PMC1974834	PMC1974834_53	[9751]	[9866]	['After transesterification, fatty acid methyl esters were separated by means of capillary gas liquid chromatography.']	fatty acid methyl esters	CHEBI_EXT	[9778]	[9802]	PMC1974834_T60
PMC1974834	PMC1974834_54	[9867]	[10066]	['The identity of each fatty acid peak was ascertained by comparison of the peak’s retention time relative to the retention times of fatty acids in a synthetic standard of known fatty acid composition.']	fatty	CHEBI_EXT	[9888]	[9893]	PMC1974834_T535
PMC1974834	PMC1974834_54	[9867]	[10066]	['The identity of each fatty acid peak was ascertained by comparison of the peak’s retention time relative to the retention times of fatty acids in a synthetic standard of known fatty acid composition.']	fatty acid	CHEBI_EXT	[9888]	[9898]	PMC1974834_T61
PMC1974834	PMC1974834_54	[9867]	[10066]	['The identity of each fatty acid peak was ascertained by comparison of the peak’s retention time relative to the retention times of fatty acids in a synthetic standard of known fatty acid composition.']	fatty	CHEBI_EXT	[9998]	[10003]	PMC1974834_T536
PMC1974834	PMC1974834_54	[9867]	[10066]	['The identity of each fatty acid peak was ascertained by comparison of the peak’s retention time relative to the retention times of fatty acids in a synthetic standard of known fatty acid composition.']	fatty acids	CHEBI_EXT	[9998]	[10009]	PMC1974834_T62
PMC1974834	PMC1974834_54	[9867]	[10066]	['The identity of each fatty acid peak was ascertained by comparison of the peak’s retention time relative to the retention times of fatty acids in a synthetic standard of known fatty acid composition.']	fatty	CHEBI_EXT	[10043]	[10048]	PMC1974834_T537
PMC1974834	PMC1974834_54	[9867]	[10066]	['The identity of each fatty acid peak was ascertained by comparison of the peak’s retention time relative to the retention times of fatty acids in a synthetic standard of known fatty acid composition.']	fatty acid	CHEBI_EXT	[10043]	[10053]	PMC1974834_T63
PMC1974834	PMC1974834_55	[10067]	[10249]	['The relative amount of each fatty acid (% of total fatty acid) was quantified by integration of the area under the peak and dividing the result by the total area for all fatty acids.']	fatty	CHEBI_EXT	[10095]	[10100]	PMC1974834_T538
PMC1974834	PMC1974834_55	[10067]	[10249]	['The relative amount of each fatty acid (% of total fatty acid) was quantified by integration of the area under the peak and dividing the result by the total area for all fatty acids.']	fatty acid	CHEBI_EXT	[10095]	[10105]	PMC1974834_T64
PMC1974834	PMC1974834_55	[10067]	[10249]	['The relative amount of each fatty acid (% of total fatty acid) was quantified by integration of the area under the peak and dividing the result by the total area for all fatty acids.']	fatty	CHEBI_EXT	[10118]	[10123]	PMC1974834_T539
PMC1974834	PMC1974834_55	[10067]	[10249]	['The relative amount of each fatty acid (% of total fatty acid) was quantified by integration of the area under the peak and dividing the result by the total area for all fatty acids.']	fatty acid	CHEBI_EXT	[10118]	[10128]	PMC1974834_T65
PMC1974834	PMC1974834_55	[10067]	[10249]	['The relative amount of each fatty acid (% of total fatty acid) was quantified by integration of the area under the peak and dividing the result by the total area for all fatty acids.']	fatty	CHEBI_EXT	[10237]	[10242]	PMC1974834_T540
PMC1974834	PMC1974834_55	[10067]	[10249]	['The relative amount of each fatty acid (% of total fatty acid) was quantified by integration of the area under the peak and dividing the result by the total area for all fatty acids.']	fatty acids	CHEBI_EXT	[10237]	[10248]	PMC1974834_T66
PMC1974834	PMC1974834_56	[10250]	[10394]	['All the analyses were performed at the Department of Clinical Chemistry, National Hospital, Oslo, under the supervision of Bjørn Christophersen.']	Chemistry	CHEBI_EXT	[10312]	[10321]	PMC1974834_T67
PMC1974834	PMC1974834_57	[10396]	[10639]	['Statistical analyses\nThe assessment of the effects of an antiatherogenic diet on markers of maternal and fetal endothelial activation and inflammation was part of the secondary hypotheses of the CARRDIP study and part of the original protocol.']	antiatherogenic	CHEBI_EXT	[10453]	[10468]	PMC1974834_T68
PMC1974834	PMC1974834_57	[10396]	[10639]	['Statistical analyses\nThe assessment of the effects of an antiatherogenic diet on markers of maternal and fetal endothelial activation and inflammation was part of the secondary hypotheses of the CARRDIP study and part of the original protocol.']	markers	CHEBI_EXT	[10477]	[10484]	PMC1974834_T69
PMC1974834	PMC1974834_57	[10396]	[10639]	['Statistical analyses\nThe assessment of the effects of an antiatherogenic diet on markers of maternal and fetal endothelial activation and inflammation was part of the secondary hypotheses of the CARRDIP study and part of the original protocol.']	endothelial	UBERON_EXT	[10507]	[10518]	PMC1974834_T541
PMC1974834	PMC1974834_57	[10396]	[10639]	['Statistical analyses\nThe assessment of the effects of an antiatherogenic diet on markers of maternal and fetal endothelial activation and inflammation was part of the secondary hypotheses of the CARRDIP study and part of the original protocol.']	endothelial activation	GO_BP_EXT	[10507]	[10529]	PMC1974834_T216
PMC1974834	PMC1974834_57	[10396]	[10639]	['Statistical analyses\nThe assessment of the effects of an antiatherogenic diet on markers of maternal and fetal endothelial activation and inflammation was part of the secondary hypotheses of the CARRDIP study and part of the original protocol.']	inflammation	GO_BP_EXT	[10534]	[10546]	PMC1974834_T217
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	cholesterol	CHEBI_EXT	[10763]	[10774]	PMC1974834_T70
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	neonatal	UBERON_EXT	[10797]	[10805]	PMC1974834_T542
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	cholesterol	CHEBI_EXT	[10812]	[10823]	PMC1974834_T71
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	women	NCBITAXON_EXT	[10909]	[10914]	PMC1974834_T330
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	women	UBERON_EXT	[10909]	[10914]	PMC1974834_T543
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	cholesterol	CHEBI_EXT	[10985]	[10996]	PMC1974834_T72
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	neonatal	UBERON_EXT	[11040]	[11048]	PMC1974834_T544
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	cholesterol	CHEBI_EXT	[11055]	[11066]	PMC1974834_T73
PMC1974834	PMC1974834_60	[11238]	[11483]	['With an expected rate of adverse pregnancy outcome of 25% (data based on the Norwegian Birth Register), this number of participants had about 65% power with α set at 0.05 to find a 50% increase in the occurrence of any adverse pregnancy outcome.']	pregnancy	GO_BP_EXT	[11271]	[11280]	PMC1974834_T218
PMC1974834	PMC1974834_60	[11238]	[11483]	['With an expected rate of adverse pregnancy outcome of 25% (data based on the Norwegian Birth Register), this number of participants had about 65% power with α set at 0.05 to find a 50% increase in the occurrence of any adverse pregnancy outcome.']	Birth	GO_BP_EXT	[11325]	[11330]	PMC1974834_T219
PMC1974834	PMC1974834_60	[11238]	[11483]	['With an expected rate of adverse pregnancy outcome of 25% (data based on the Norwegian Birth Register), this number of participants had about 65% power with α set at 0.05 to find a 50% increase in the occurrence of any adverse pregnancy outcome.']	pregnancy	GO_BP_EXT	[11465]	[11474]	PMC1974834_T220
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	intake	GO_BP_EXT	[11503]	[11509]	PMC1974834_T221
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	macronutrients	CHEBI_EXT	[11513]	[11527]	PMC1974834_T74
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	food stuffs	CHEBI_EXT	[11532]	[11543]	PMC1974834_T75
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	pregnancy	GO_BP_EXT	[11551]	[11560]	PMC1974834_T222
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	intake	GO_BP_EXT	[11590]	[11596]	PMC1974834_T223
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	intake	GO_BP_EXT	[11629]	[11635]	PMC1974834_T224
PMC1974834	PMC1974834_64	[11873]	[11988]	['The tPAag concentrations in cord blood did not follow a normal distribution; hence, a Mann–Whitney U test was used.']	cord	UBERON_EXT	[11901]	[11905]	PMC1974834_T545
PMC1974834	PMC1974834_64	[11873]	[11988]	['The tPAag concentrations in cord blood did not follow a normal distribution; hence, a Mann–Whitney U test was used.']	blood	UBERON_EXT	[11906]	[11911]	PMC1974834_T546
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	WRAP	PR_EXT	[12229]	[12233]	PMC1974834_T393
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	markers	CHEBI_EXT	[12263]	[12270]	PMC1974834_T76
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	markers	SO_EXT	[12263]	[12270]	PMC1974834_T455
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	endothelial	UBERON_EXT	[12274]	[12285]	PMC1974834_T547
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	endothelial activation	GO_BP_EXT	[12274]	[12296]	PMC1974834_T225
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	prothrombotic	GO_BP_EXT	[12301]	[12314]	PMC1974834_T226
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	cord	UBERON_EXT	[12327]	[12331]	PMC1974834_T548
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	blood	UBERON_EXT	[12332]	[12337]	PMC1974834_T549
PMC1974834	PMC1974834_68	[12380]	[12846]	['control/interventionControlIntervention P value*VCAM-1 (ng/ml)120/119813 (695, 970)836 (715, 993)0.4ICAM-1 (ng/ml)120/119149 (130, 167)148 (128, 174)0.7E-selectin (ng/ml)120/118150 (96.7, 189)159 (123, 201)0.08tPAag (ng/ml)119/1175.8 (3.5, 11.8)5.4 (3.1, 7.7)0.2vWF (%)107/10491 (66, 135)82 (54, 120)0.3PAI-1 activity (u/ml)118/1159.3 (4.6, 17.8)10.3 (5, 19)0.6PAI-2 antigen (ng/ml)119/1143.4 (1.1, 9.4)3.7 (1.9, 6.7)0.6\nValues shown are median (25, 75 percentiles).']	VCAM-1	PR_EXT	[12428]	[12434]	PMC1974834_T394
PMC1974834	PMC1974834_68	[12380]	[12846]	['control/interventionControlIntervention P value*VCAM-1 (ng/ml)120/119813 (695, 970)836 (715, 993)0.4ICAM-1 (ng/ml)120/119149 (130, 167)148 (128, 174)0.7E-selectin (ng/ml)120/118150 (96.7, 189)159 (123, 201)0.08tPAag (ng/ml)119/1175.8 (3.5, 11.8)5.4 (3.1, 7.7)0.2vWF (%)107/10491 (66, 135)82 (54, 120)0.3PAI-1 activity (u/ml)118/1159.3 (4.6, 17.8)10.3 (5, 19)0.6PAI-2 antigen (ng/ml)119/1143.4 (1.1, 9.4)3.7 (1.9, 6.7)0.6\nValues shown are median (25, 75 percentiles).']	4ICAM-1	PR_EXT	[12479]	[12486]	PMC1974834_T395
PMC1974834	PMC1974834_68	[12380]	[12846]	['control/interventionControlIntervention P value*VCAM-1 (ng/ml)120/119813 (695, 970)836 (715, 993)0.4ICAM-1 (ng/ml)120/119149 (130, 167)148 (128, 174)0.7E-selectin (ng/ml)120/118150 (96.7, 189)159 (123, 201)0.08tPAag (ng/ml)119/1175.8 (3.5, 11.8)5.4 (3.1, 7.7)0.2vWF (%)107/10491 (66, 135)82 (54, 120)0.3PAI-1 activity (u/ml)118/1159.3 (4.6, 17.8)10.3 (5, 19)0.6PAI-2 antigen (ng/ml)119/1143.4 (1.1, 9.4)3.7 (1.9, 6.7)0.6\nValues shown are median (25, 75 percentiles).']	-selectin	PR_EXT	[12533]	[12542]	PMC1974834_T396
PMC1974834	PMC1974834_68	[12380]	[12846]	['control/interventionControlIntervention P value*VCAM-1 (ng/ml)120/119813 (695, 970)836 (715, 993)0.4ICAM-1 (ng/ml)120/119149 (130, 167)148 (128, 174)0.7E-selectin (ng/ml)120/118150 (96.7, 189)159 (123, 201)0.08tPAag (ng/ml)119/1175.8 (3.5, 11.8)5.4 (3.1, 7.7)0.2vWF (%)107/10491 (66, 135)82 (54, 120)0.3PAI-1 activity (u/ml)118/1159.3 (4.6, 17.8)10.3 (5, 19)0.6PAI-2 antigen (ng/ml)119/1143.4 (1.1, 9.4)3.7 (1.9, 6.7)0.6\nValues shown are median (25, 75 percentiles).']	-1	PR_EXT	[12686]	[12688]	PMC1974834_T397
PMC1974834	PMC1974834_68	[12380]	[12846]	['control/interventionControlIntervention P value*VCAM-1 (ng/ml)120/119813 (695, 970)836 (715, 993)0.4ICAM-1 (ng/ml)120/119149 (130, 167)148 (128, 174)0.7E-selectin (ng/ml)120/118150 (96.7, 189)159 (123, 201)0.08tPAag (ng/ml)119/1175.8 (3.5, 11.8)5.4 (3.1, 7.7)0.2vWF (%)107/10491 (66, 135)82 (54, 120)0.3PAI-1 activity (u/ml)118/1159.3 (4.6, 17.8)10.3 (5, 19)0.6PAI-2 antigen (ng/ml)119/1143.4 (1.1, 9.4)3.7 (1.9, 6.7)0.6\nValues shown are median (25, 75 percentiles).']	-2	PR_EXT	[12744]	[12746]	PMC1974834_T398
PMC1974834	PMC1974834_68	[12380]	[12846]	['control/interventionControlIntervention P value*VCAM-1 (ng/ml)120/119813 (695, 970)836 (715, 993)0.4ICAM-1 (ng/ml)120/119149 (130, 167)148 (128, 174)0.7E-selectin (ng/ml)120/118150 (96.7, 189)159 (123, 201)0.08tPAag (ng/ml)119/1175.8 (3.5, 11.8)5.4 (3.1, 7.7)0.2vWF (%)107/10491 (66, 135)82 (54, 120)0.3PAI-1 activity (u/ml)118/1159.3 (4.6, 17.8)10.3 (5, 19)0.6PAI-2 antigen (ng/ml)119/1143.4 (1.1, 9.4)3.7 (1.9, 6.7)0.6\nValues shown are median (25, 75 percentiles).']	antigen	CHEBI_EXT	[12747]	[12754]	PMC1974834_T77
PMC1974834	PMC1974834_70	[12890]	[13007]	['Boxplots were used to describe the concentrations of the biomarkers at different time points during the study period.']	biomarkers	CHEBI_EXT	[12947]	[12957]	PMC1974834_T78
PMC1974834	PMC1974834_70	[12890]	[13007]	['Boxplots were used to describe the concentrations of the biomarkers at different time points during the study period.']	biomarkers	CHEBI_EXT	[12947]	[12957]	PMC1974834_T456
PMC1974834	PMC1974834_71	[13008]	[13340]	['CRP values higher than 10 mg/l were excluded because of a number of confounding causes of elevated CRP.24The number of excluded cases due to elevated CRP in the control and intervention groups, respectively, were as follows: n = 24 and 11 at baseline, n = 10 and 12 at week 24, n = 15 and 10 at week 30 and n = 11 and 11 at week 36.']	CRP	PR_EXT	[13008]	[13011]	PMC1974834_T399
PMC1974834	PMC1974834_71	[13008]	[13340]	['CRP values higher than 10 mg/l were excluded because of a number of confounding causes of elevated CRP.24The number of excluded cases due to elevated CRP in the control and intervention groups, respectively, were as follows: n = 24 and 11 at baseline, n = 10 and 12 at week 24, n = 15 and 10 at week 30 and n = 11 and 11 at week 36.']	CRP	CHEBI_EXT	[13107]	[13110]	PMC1974834_T79
PMC1974834	PMC1974834_71	[13008]	[13340]	['CRP values higher than 10 mg/l were excluded because of a number of confounding causes of elevated CRP.24The number of excluded cases due to elevated CRP in the control and intervention groups, respectively, were as follows: n = 24 and 11 at baseline, n = 10 and 12 at week 24, n = 15 and 10 at week 30 and n = 11 and 11 at week 36.']	CRP	PR_EXT	[13107]	[13110]	PMC1974834_T400
PMC1974834	PMC1974834_73	[13501]	[13664]	['Pearson’s correlation coefficient was used to assess correlation between baseline CRP and baseline body mass index (BMI) in the entire cohort before randomisation.']	CRP	CHEBI_EXT	[13583]	[13586]	PMC1974834_T80
PMC1974834	PMC1974834_73	[13501]	[13664]	['Pearson’s correlation coefficient was used to assess correlation between baseline CRP and baseline body mass index (BMI) in the entire cohort before randomisation.']	CRP	PR_EXT	[13583]	[13586]	PMC1974834_T401
PMC1974834	PMC1974834_73	[13501]	[13664]	['Pearson’s correlation coefficient was used to assess correlation between baseline CRP and baseline body mass index (BMI) in the entire cohort before randomisation.']	body	UBERON_EXT	[13600]	[13604]	PMC1974834_T550
PMC1974834	PMC1974834_76	[13808]	[13865]	['Results\nThe intention-to-treat cohort included 290 women.']	women	NCBITAXON_EXT	[13859]	[13864]	PMC1974834_T331
PMC1974834	PMC1974834_76	[13808]	[13865]	['Results\nThe intention-to-treat cohort included 290 women.']	women	UBERON_EXT	[13859]	[13864]	PMC1974834_T551
PMC1974834	PMC1974834_79	[14056]	[14610]	['No differences in baseline characteristics or dietary variables between the groups were observed before randomisation.9\n\nCaption (TABLE-WRAP): TABLE 1\n\nCharacteristics of participants at baselineCharacteristicControlIntervention P -valueNo.149141Age (years)29.8 (3.4)29.6 (3.7)0.7Nulliparous (%)65.170.90.3Gestational age at entry (week)19 (1.1)19 (1.1)0.919 (5.4)*19 (4.9)*BMI (kg/m2)24.3 (2.7)24.3 (2.9)0.9BMI (%) >25 (kg/m2)32.936.20.6Systolic blood pressure (mmHg)105 (10)106 (9)0.9Diastolic blood pressure (mmHg)65 (8)64 (8)0.4\nValues are mean (SD).']	blood	UBERON_EXT	[14503]	[14508]	PMC1974834_T552
PMC1974834	PMC1974834_79	[14056]	[14610]	['No differences in baseline characteristics or dietary variables between the groups were observed before randomisation.9\n\nCaption (TABLE-WRAP): TABLE 1\n\nCharacteristics of participants at baselineCharacteristicControlIntervention P -valueNo.149141Age (years)29.8 (3.4)29.6 (3.7)0.7Nulliparous (%)65.170.90.3Gestational age at entry (week)19 (1.1)19 (1.1)0.919 (5.4)*19 (4.9)*BMI (kg/m2)24.3 (2.7)24.3 (2.9)0.9BMI (%) >25 (kg/m2)32.936.20.6Systolic blood pressure (mmHg)105 (10)106 (9)0.9Diastolic blood pressure (mmHg)65 (8)64 (8)0.4\nValues are mean (SD).']	blood	UBERON_EXT	[14552]	[14557]	PMC1974834_T553
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	intake	GO_BP_EXT	[14682]	[14688]	PMC1974834_T227
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	gestation	GO_BP_EXT	[14706]	[14715]	PMC1974834_T228
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	consumed	GO_BP_EXT	[14748]	[14756]	PMC1974834_T229
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	fat	CHEBI_EXT	[14779]	[14782]	PMC1974834_T81
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	fat	CHEBI_EXT	[14779]	[14782]	PMC1974834_T554
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	saturated fat	CHEBI_EXT	[14841]	[14854]	PMC1974834_T82
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	fat	CHEBI_EXT	[14851]	[14854]	PMC1974834_T555
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	cholesterol	CHEBI_EXT	[14867]	[14878]	PMC1974834_T83
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	fatty	CHEBI_EXT	[14974]	[14979]	PMC1974834_T84
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	intake	GO_BP_EXT	[15037]	[15043]	PMC1974834_T230
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	fish	NCBITAXON_EXT	[15047]	[15051]	PMC1974834_T332
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	fish	NCBITAXON_EXT	[15056]	[15060]	PMC1974834_T333
PMC1974834	PMC1974834_82	[15071]	[15245]	['Mean dietary intake of fatty fish and fish products during the study period was also significantly higher in the intervention group compared with the control group (Table 2).']	fatty fish	CHEBI_EXT	[15094]	[15104]	PMC1974834_T85
PMC1974834	PMC1974834_82	[15071]	[15245]	['Mean dietary intake of fatty fish and fish products during the study period was also significantly higher in the intervention group compared with the control group (Table 2).']	fish	NCBITAXON_EXT	[15100]	[15104]	PMC1974834_T334
PMC1974834	PMC1974834_82	[15071]	[15245]	['Mean dietary intake of fatty fish and fish products during the study period was also significantly higher in the intervention group compared with the control group (Table 2).']	fish	CHEBI_EXT	[15109]	[15113]	PMC1974834_T86
PMC1974834	PMC1974834_82	[15071]	[15245]	['Mean dietary intake of fatty fish and fish products during the study period was also significantly higher in the intervention group compared with the control group (Table 2).']	fish	NCBITAXON_EXT	[15109]	[15113]	PMC1974834_T335
PMC1974834	PMC1974834_83	[15246]	[15361]	['In addition, the intervention group increased their use of monounsaturated oils, mainly olive oil and rapeseed oil.']	monounsaturated	CHEBI_EXT	[15305]	[15320]	PMC1974834_T87
PMC1974834	PMC1974834_84	[15362]	[15527]	['Moreover, the consumption of nuts, olives, seeds, fruits and vegetables was significantly higher in the intervention group compared with the control group (Table 2).']	consumption	GO_BP_EXT	[15376]	[15387]	PMC1974834_T231
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	intake	GO_BP_EXT	[15584]	[15590]	PMC1974834_T232
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	food	CHEBI_EXT	[15604]	[15608]	PMC1974834_T88
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	fat	CHEBI_EXT	[15757]	[15760]	PMC1974834_T89
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	fat	CHEBI_EXT	[15757]	[15760]	PMC1974834_T556
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Protein	CHEBI_EXT	[15802]	[15809]	PMC1974834_T90
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Protein	CHEBI_EXT	[15802]	[15809]	PMC1974834_T402
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Carbohydrates	CHEBI_EXT	[15851]	[15864]	PMC1974834_T91
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	milk	UBERON_EXT	[15953]	[15957]	PMC1974834_T557
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	milk	UBERON_EXT	[16003]	[16007]	PMC1974834_T558
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Meat	UBERON_EXT	[16078]	[16082]	PMC1974834_T559
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Fatty	CHEBI_EXT	[16138]	[16143]	PMC1974834_T92
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Fatty	CHEBI_EXT	[16138]	[16143]	PMC1974834_T560
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	meat	UBERON_EXT	[16151]	[16155]	PMC1974834_T561
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Fish	NCBITAXON_EXT	[16187]	[16191]	PMC1974834_T336
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	fish	NCBITAXON_EXT	[16196]	[16200]	PMC1974834_T337
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	fish	NCBITAXON_EXT	[16253]	[16257]	PMC1974834_T338
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Butter	CHEBI_EXT	[16298]	[16304]	PMC1974834_T93
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	margarines	CHEBI_EXT	[16344]	[16354]	PMC1974834_T94
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	margarines	CHEBI_EXT	[16393]	[16403]	PMC1974834_T95
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	margarine0	CHEBI_EXT	[16450]	[16460]	PMC1974834_T96
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Oils	CHEBI_EXT	[16485]	[16489]	PMC1974834_T97
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Vegetables	CHEBI_EXT	[16646]	[16656]	PMC1974834_T98
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Fruits	UBERON_EXT	[16691]	[16697]	PMC1974834_T562
PMC1974834	PMC1974834_86	[16760]	[17061]	['The increase in myristic acid (C14:0) level in serum total fatty acids from baseline to week 36 was significantly lower in the intervention group compared with the control group, while eicosapentaenic acid (C20:5) levels tended to increase more in the intervention than in the control group (Table 3).']	myristic acid	CHEBI_EXT	[16776]	[16789]	PMC1974834_T99
PMC1974834	PMC1974834_86	[16760]	[17061]	['The increase in myristic acid (C14:0) level in serum total fatty acids from baseline to week 36 was significantly lower in the intervention group compared with the control group, while eicosapentaenic acid (C20:5) levels tended to increase more in the intervention than in the control group (Table 3).']	serum	UBERON_EXT	[16807]	[16812]	PMC1974834_T563
PMC1974834	PMC1974834_86	[16760]	[17061]	['The increase in myristic acid (C14:0) level in serum total fatty acids from baseline to week 36 was significantly lower in the intervention group compared with the control group, while eicosapentaenic acid (C20:5) levels tended to increase more in the intervention than in the control group (Table 3).']	fatty	CHEBI_EXT	[16819]	[16824]	PMC1974834_T564
PMC1974834	PMC1974834_86	[16760]	[17061]	['The increase in myristic acid (C14:0) level in serum total fatty acids from baseline to week 36 was significantly lower in the intervention group compared with the control group, while eicosapentaenic acid (C20:5) levels tended to increase more in the intervention than in the control group (Table 3).']	fatty acids	CHEBI_EXT	[16819]	[16830]	PMC1974834_T100
PMC1974834	PMC1974834_86	[16760]	[17061]	['The increase in myristic acid (C14:0) level in serum total fatty acids from baseline to week 36 was significantly lower in the intervention group compared with the control group, while eicosapentaenic acid (C20:5) levels tended to increase more in the intervention than in the control group (Table 3).']	eicosapentaenic acid	CHEBI_EXT	[16945]	[16965]	PMC1974834_T101
PMC1974834	PMC1974834_86	[16760]	[17061]	['The increase in myristic acid (C14:0) level in serum total fatty acids from baseline to week 36 was significantly lower in the intervention group compared with the control group, while eicosapentaenic acid (C20:5) levels tended to increase more in the intervention than in the control group (Table 3).']	C20	CHEBI_EXT	[16967]	[16970]	PMC1974834_T102
PMC1974834	PMC1974834_87	[17063]	[17982]	['Caption (TABLE-WRAP): TABLE 3\n\nFatty acid composition (% of total serum fatty acids) at baseline and week 36Control ( n = 129)Intervention ( n = 125) P *BaselineWeek 36BaselineWeek 36C14:00 (0, 0)0 (0, 0.7)0 (0, 0)0 (0, 0.6)0.02C14:0**0.15 (0.33)0.35 (0.39)0.18 (0.33)0.28 (0.38)C16:026.5 (25.3, 28.1)29.5 (28.1, 31.4)26.5 (25.2, 27.9)29.3 (27.5, 31.0)0.4C18:07.5 (6.7, 8.1)7.2 (6.3, 7.8)7.6 (6.9, 8.1)7.0 (6.5, 7.6)0.1C18:121.1 (19.6, 22.5)21.8 (20.3, 24.0)20.7 (19.2, 22.2)22.2 (20.5, 24.2)0.3C18:227.6 (25.4, 29.9)25.6 (24.3, 28.6)27.7 (25.3, 30.6)26.3 (24.4, 28.6)0.7C18:30.7 (0, 0.8)0.7 (0.5, 0.8)0.7 (0, 0.8)0.7 (0, 0.8)0.8C20:47.0 (6.1, 7.8)5.9 (5.2, 6.7)6.9 (6.2, 7.9)5.9 (5.1, 6.7)0.1C20:50.9 (0.4, 1.4)0.6 (0, 1.0)1.0 (0, 1.5)0.7 (0,1.4)0.06C22:67.6 (5.9, 9.6)6.5 (4.7, 8.5)7.6 (5.9, 9.4)6.7 (5.0, 8.5)0.7\nData are shown as median (25,75 percentiles), except for C14:0 where\nmean (SD) values are supplemented.']	Fatty	CHEBI_EXT	[17094]	[17099]	PMC1974834_T565
PMC1974834	PMC1974834_87	[17063]	[17982]	['Caption (TABLE-WRAP): TABLE 3\n\nFatty acid composition (% of total serum fatty acids) at baseline and week 36Control ( n = 129)Intervention ( n = 125) P *BaselineWeek 36BaselineWeek 36C14:00 (0, 0)0 (0, 0.7)0 (0, 0)0 (0, 0.6)0.02C14:0**0.15 (0.33)0.35 (0.39)0.18 (0.33)0.28 (0.38)C16:026.5 (25.3, 28.1)29.5 (28.1, 31.4)26.5 (25.2, 27.9)29.3 (27.5, 31.0)0.4C18:07.5 (6.7, 8.1)7.2 (6.3, 7.8)7.6 (6.9, 8.1)7.0 (6.5, 7.6)0.1C18:121.1 (19.6, 22.5)21.8 (20.3, 24.0)20.7 (19.2, 22.2)22.2 (20.5, 24.2)0.3C18:227.6 (25.4, 29.9)25.6 (24.3, 28.6)27.7 (25.3, 30.6)26.3 (24.4, 28.6)0.7C18:30.7 (0, 0.8)0.7 (0.5, 0.8)0.7 (0, 0.8)0.7 (0, 0.8)0.8C20:47.0 (6.1, 7.8)5.9 (5.2, 6.7)6.9 (6.2, 7.9)5.9 (5.1, 6.7)0.1C20:50.9 (0.4, 1.4)0.6 (0, 1.0)1.0 (0, 1.5)0.7 (0,1.4)0.06C22:67.6 (5.9, 9.6)6.5 (4.7, 8.5)7.6 (5.9, 9.4)6.7 (5.0, 8.5)0.7\nData are shown as median (25,75 percentiles), except for C14:0 where\nmean (SD) values are supplemented.']	Fatty acid	CHEBI_EXT	[17094]	[17104]	PMC1974834_T103
PMC1974834	PMC1974834_87	[17063]	[17982]	['Caption (TABLE-WRAP): TABLE 3\n\nFatty acid composition (% of total serum fatty acids) at baseline and week 36Control ( n = 129)Intervention ( n = 125) P *BaselineWeek 36BaselineWeek 36C14:00 (0, 0)0 (0, 0.7)0 (0, 0)0 (0, 0.6)0.02C14:0**0.15 (0.33)0.35 (0.39)0.18 (0.33)0.28 (0.38)C16:026.5 (25.3, 28.1)29.5 (28.1, 31.4)26.5 (25.2, 27.9)29.3 (27.5, 31.0)0.4C18:07.5 (6.7, 8.1)7.2 (6.3, 7.8)7.6 (6.9, 8.1)7.0 (6.5, 7.6)0.1C18:121.1 (19.6, 22.5)21.8 (20.3, 24.0)20.7 (19.2, 22.2)22.2 (20.5, 24.2)0.3C18:227.6 (25.4, 29.9)25.6 (24.3, 28.6)27.7 (25.3, 30.6)26.3 (24.4, 28.6)0.7C18:30.7 (0, 0.8)0.7 (0.5, 0.8)0.7 (0, 0.8)0.7 (0, 0.8)0.8C20:47.0 (6.1, 7.8)5.9 (5.2, 6.7)6.9 (6.2, 7.9)5.9 (5.1, 6.7)0.1C20:50.9 (0.4, 1.4)0.6 (0, 1.0)1.0 (0, 1.5)0.7 (0,1.4)0.06C22:67.6 (5.9, 9.6)6.5 (4.7, 8.5)7.6 (5.9, 9.4)6.7 (5.0, 8.5)0.7\nData are shown as median (25,75 percentiles), except for C14:0 where\nmean (SD) values are supplemented.']	serum	UBERON_EXT	[17129]	[17134]	PMC1974834_T566
PMC1974834	PMC1974834_87	[17063]	[17982]	['Caption (TABLE-WRAP): TABLE 3\n\nFatty acid composition (% of total serum fatty acids) at baseline and week 36Control ( n = 129)Intervention ( n = 125) P *BaselineWeek 36BaselineWeek 36C14:00 (0, 0)0 (0, 0.7)0 (0, 0)0 (0, 0.6)0.02C14:0**0.15 (0.33)0.35 (0.39)0.18 (0.33)0.28 (0.38)C16:026.5 (25.3, 28.1)29.5 (28.1, 31.4)26.5 (25.2, 27.9)29.3 (27.5, 31.0)0.4C18:07.5 (6.7, 8.1)7.2 (6.3, 7.8)7.6 (6.9, 8.1)7.0 (6.5, 7.6)0.1C18:121.1 (19.6, 22.5)21.8 (20.3, 24.0)20.7 (19.2, 22.2)22.2 (20.5, 24.2)0.3C18:227.6 (25.4, 29.9)25.6 (24.3, 28.6)27.7 (25.3, 30.6)26.3 (24.4, 28.6)0.7C18:30.7 (0, 0.8)0.7 (0.5, 0.8)0.7 (0, 0.8)0.7 (0, 0.8)0.8C20:47.0 (6.1, 7.8)5.9 (5.2, 6.7)6.9 (6.2, 7.9)5.9 (5.1, 6.7)0.1C20:50.9 (0.4, 1.4)0.6 (0, 1.0)1.0 (0, 1.5)0.7 (0,1.4)0.06C22:67.6 (5.9, 9.6)6.5 (4.7, 8.5)7.6 (5.9, 9.4)6.7 (5.0, 8.5)0.7\nData are shown as median (25,75 percentiles), except for C14:0 where\nmean (SD) values are supplemented.']	fatty	CHEBI_EXT	[17135]	[17140]	PMC1974834_T567
PMC1974834	PMC1974834_87	[17063]	[17982]	['Caption (TABLE-WRAP): TABLE 3\n\nFatty acid composition (% of total serum fatty acids) at baseline and week 36Control ( n = 129)Intervention ( n = 125) P *BaselineWeek 36BaselineWeek 36C14:00 (0, 0)0 (0, 0.7)0 (0, 0)0 (0, 0.6)0.02C14:0**0.15 (0.33)0.35 (0.39)0.18 (0.33)0.28 (0.38)C16:026.5 (25.3, 28.1)29.5 (28.1, 31.4)26.5 (25.2, 27.9)29.3 (27.5, 31.0)0.4C18:07.5 (6.7, 8.1)7.2 (6.3, 7.8)7.6 (6.9, 8.1)7.0 (6.5, 7.6)0.1C18:121.1 (19.6, 22.5)21.8 (20.3, 24.0)20.7 (19.2, 22.2)22.2 (20.5, 24.2)0.3C18:227.6 (25.4, 29.9)25.6 (24.3, 28.6)27.7 (25.3, 30.6)26.3 (24.4, 28.6)0.7C18:30.7 (0, 0.8)0.7 (0.5, 0.8)0.7 (0, 0.8)0.7 (0, 0.8)0.8C20:47.0 (6.1, 7.8)5.9 (5.2, 6.7)6.9 (6.2, 7.9)5.9 (5.1, 6.7)0.1C20:50.9 (0.4, 1.4)0.6 (0, 1.0)1.0 (0, 1.5)0.7 (0,1.4)0.06C22:67.6 (5.9, 9.6)6.5 (4.7, 8.5)7.6 (5.9, 9.4)6.7 (5.0, 8.5)0.7\nData are shown as median (25,75 percentiles), except for C14:0 where\nmean (SD) values are supplemented.']	fatty acids	CHEBI_EXT	[17135]	[17146]	PMC1974834_T104
PMC1974834	PMC1974834_89	[18045]	[18440]	['Maternal biomarkers and the dietary intervention\nOver the duration of the study period (between baseline and week 36), there was a significant increase in the concentrations of sCAMs and the haemostatic markers both within the intervention and control groups analysed separately (Figures 2and3; P< 0.01 for all variables) and within the entire cohort (data not shown; P< 0.01 for all variables).']	biomarkers	CHEBI_EXT	[18054]	[18064]	PMC1974834_T105
PMC1974834	PMC1974834_89	[18045]	[18440]	['Maternal biomarkers and the dietary intervention\nOver the duration of the study period (between baseline and week 36), there was a significant increase in the concentrations of sCAMs and the haemostatic markers both within the intervention and control groups analysed separately (Figures 2and3; P< 0.01 for all variables) and within the entire cohort (data not shown; P< 0.01 for all variables).']	biomarkers	CHEBI_EXT	[18054]	[18064]	PMC1974834_T457
PMC1974834	PMC1974834_89	[18045]	[18440]	['Maternal biomarkers and the dietary intervention\nOver the duration of the study period (between baseline and week 36), there was a significant increase in the concentrations of sCAMs and the haemostatic markers both within the intervention and control groups analysed separately (Figures 2and3; P< 0.01 for all variables) and within the entire cohort (data not shown; P< 0.01 for all variables).']	haemostatic	GO_BP_EXT	[18236]	[18247]	PMC1974834_T233
PMC1974834	PMC1974834_89	[18045]	[18440]	['Maternal biomarkers and the dietary intervention\nOver the duration of the study period (between baseline and week 36), there was a significant increase in the concentrations of sCAMs and the haemostatic markers both within the intervention and control groups analysed separately (Figures 2and3; P< 0.01 for all variables) and within the entire cohort (data not shown; P< 0.01 for all variables).']	markers	CHEBI_EXT	[18248]	[18255]	PMC1974834_T106
PMC1974834	PMC1974834_89	[18045]	[18440]	['Maternal biomarkers and the dietary intervention\nOver the duration of the study period (between baseline and week 36), there was a significant increase in the concentrations of sCAMs and the haemostatic markers both within the intervention and control groups analysed separately (Figures 2and3; P< 0.01 for all variables) and within the entire cohort (data not shown; P< 0.01 for all variables).']	markers	SO_EXT	[18248]	[18255]	PMC1974834_T458
PMC1974834	PMC1974834_89	[18045]	[18440]	['Maternal biomarkers and the dietary intervention\nOver the duration of the study period (between baseline and week 36), there was a significant increase in the concentrations of sCAMs and the haemostatic markers both within the intervention and control groups analysed separately (Figures 2and3; P< 0.01 for all variables) and within the entire cohort (data not shown; P< 0.01 for all variables).']	variables	CHEBI_EXT	[18356]	[18365]	PMC1974834_T107
PMC1974834	PMC1974834_89	[18045]	[18440]	['Maternal biomarkers and the dietary intervention\nOver the duration of the study period (between baseline and week 36), there was a significant increase in the concentrations of sCAMs and the haemostatic markers both within the intervention and control groups analysed separately (Figures 2and3; P< 0.01 for all variables) and within the entire cohort (data not shown; P< 0.01 for all variables).']	variables	CHEBI_EXT	[18429]	[18438]	PMC1974834_T108
PMC1974834	PMC1974834_90	[18441]	[18624]	['However, the concentrations of CRP did not increase within the intervention and control groups analysed separately (Figure 2d, P> 0.1) or as an entire cohort (data not shown, P> 0.1).']	CRP	CHEBI_EXT	[18472]	[18475]	PMC1974834_T109
PMC1974834	PMC1974834_90	[18441]	[18624]	['However, the concentrations of CRP did not increase within the intervention and control groups analysed separately (Figure 2d, P> 0.1) or as an entire cohort (data not shown, P> 0.1).']	CRP	PR_EXT	[18472]	[18475]	PMC1974834_T403
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	sCAMs	PR_EXT	[18643]	[18648]	PMC1974834_T404
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	CRP	PR_EXT	[18650]	[18653]	PMC1974834_T405
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	haemostatic	GO_BP_EXT	[18662]	[18673]	PMC1974834_T234
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	markers	CHEBI_EXT	[18674]	[18681]	PMC1974834_T110
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	markers	SO_EXT	[18674]	[18681]	PMC1974834_T459
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	markers	CHEBI_EXT	[18846]	[18853]	PMC1974834_T111
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	markers	SO_EXT	[18846]	[18853]	PMC1974834_T460
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	gestation	GO_BP_EXT	[18859]	[18868]	PMC1974834_T235
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	gestation	GO_BP_EXT	[18894]	[18903]	PMC1974834_T236
PMC1974834	PMC1974834_92	[18914]	[19093]	['In the total study population (control and intervention groups combined), a positive significant correlation was found between baseline CRP and baseline BMI ( r = 0.27, P = 0.01).']	CRP	CHEBI_EXT	[19050]	[19053]	PMC1974834_T112
PMC1974834	PMC1974834_92	[18914]	[19093]	['In the total study population (control and intervention groups combined), a positive significant correlation was found between baseline CRP and baseline BMI ( r = 0.27, P = 0.01).']	CRP	GO_MF_EXT	[19050]	[19053]	PMC1974834_T315
PMC1974834	PMC1974834_92	[18914]	[19093]	['In the total study population (control and intervention groups combined), a positive significant correlation was found between baseline CRP and baseline BMI ( r = 0.27, P = 0.01).']	CRP	PR_EXT	[19050]	[19053]	PMC1974834_T406
PMC1974834	PMC1974834_93	[19095]	[19283]	['Caption (FIG): FIGURE 2\n\nBoxplot for the concentrations of sCAMs and high-sensitivity (Hs) CRP (CRP values >10 not included) during the study period in the control and intervention groups.']	CRP	PR_EXT	[19186]	[19189]	PMC1974834_T407
PMC1974834	PMC1974834_93	[19095]	[19283]	['Caption (FIG): FIGURE 2\n\nBoxplot for the concentrations of sCAMs and high-sensitivity (Hs) CRP (CRP values >10 not included) during the study period in the control and intervention groups.']	CRP	PR_EXT	[19191]	[19194]	PMC1974834_T408
PMC1974834	PMC1974834_94	[19284]	[19416]	['P values refer to group differences expressed as changes in those markers from gestation week 17–20 (baseline) to gestation week 36.']	markers	CHEBI_EXT	[19350]	[19357]	PMC1974834_T113
PMC1974834	PMC1974834_94	[19284]	[19416]	['P values refer to group differences expressed as changes in those markers from gestation week 17–20 (baseline) to gestation week 36.']	markers	SO_EXT	[19350]	[19357]	PMC1974834_T461
PMC1974834	PMC1974834_94	[19284]	[19416]	['P values refer to group differences expressed as changes in those markers from gestation week 17–20 (baseline) to gestation week 36.']	gestation	GO_BP_EXT	[19363]	[19372]	PMC1974834_T237
PMC1974834	PMC1974834_94	[19284]	[19416]	['P values refer to group differences expressed as changes in those markers from gestation week 17–20 (baseline) to gestation week 36.']	gestation	GO_BP_EXT	[19398]	[19407]	PMC1974834_T238
PMC1974834	PMC1974834_95	[19418]	[19600]	['Caption (FIG): FIGURE 3\n\nBoxplot for the concentrations of the haemostatic markers (markers of prothrombotic activity) during the study period in the control and intervention groups.']	haemostatic	GO_BP_EXT	[19481]	[19492]	PMC1974834_T239
PMC1974834	PMC1974834_95	[19418]	[19600]	['Caption (FIG): FIGURE 3\n\nBoxplot for the concentrations of the haemostatic markers (markers of prothrombotic activity) during the study period in the control and intervention groups.']	markers	CHEBI_EXT	[19493]	[19500]	PMC1974834_T114
PMC1974834	PMC1974834_95	[19418]	[19600]	['Caption (FIG): FIGURE 3\n\nBoxplot for the concentrations of the haemostatic markers (markers of prothrombotic activity) during the study period in the control and intervention groups.']	markers	SO_EXT	[19493]	[19500]	PMC1974834_T462
PMC1974834	PMC1974834_95	[19418]	[19600]	['Caption (FIG): FIGURE 3\n\nBoxplot for the concentrations of the haemostatic markers (markers of prothrombotic activity) during the study period in the control and intervention groups.']	markers	CHEBI_EXT	[19502]	[19509]	PMC1974834_T115
PMC1974834	PMC1974834_95	[19418]	[19600]	['Caption (FIG): FIGURE 3\n\nBoxplot for the concentrations of the haemostatic markers (markers of prothrombotic activity) during the study period in the control and intervention groups.']	markers	SO_EXT	[19502]	[19509]	PMC1974834_T463
PMC1974834	PMC1974834_95	[19418]	[19600]	['Caption (FIG): FIGURE 3\n\nBoxplot for the concentrations of the haemostatic markers (markers of prothrombotic activity) during the study period in the control and intervention groups.']	prothrombotic	GO_BP_EXT	[19513]	[19526]	PMC1974834_T240
PMC1974834	PMC1974834_96	[19601]	[19743]	['P values refer to group differences expressed as changes in the haemostatic markers from gestation week 17–20 (baseline) to gestation week 36.']	haemostatic	GO_BP_EXT	[19665]	[19676]	PMC1974834_T241
PMC1974834	PMC1974834_96	[19601]	[19743]	['P values refer to group differences expressed as changes in the haemostatic markers from gestation week 17–20 (baseline) to gestation week 36.']	markers	CHEBI_EXT	[19677]	[19684]	PMC1974834_T116
PMC1974834	PMC1974834_96	[19601]	[19743]	['P values refer to group differences expressed as changes in the haemostatic markers from gestation week 17–20 (baseline) to gestation week 36.']	markers	SO_EXT	[19677]	[19684]	PMC1974834_T464
PMC1974834	PMC1974834_96	[19601]	[19743]	['P values refer to group differences expressed as changes in the haemostatic markers from gestation week 17–20 (baseline) to gestation week 36.']	gestation	GO_BP_EXT	[19690]	[19699]	PMC1974834_T242
PMC1974834	PMC1974834_96	[19601]	[19743]	['P values refer to group differences expressed as changes in the haemostatic markers from gestation week 17–20 (baseline) to gestation week 36.']	gestation	GO_BP_EXT	[19725]	[19734]	PMC1974834_T243
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	Biomarkers	CHEBI_EXT	[19745]	[19755]	PMC1974834_T117
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	Biomarkers	CHEBI_EXT	[19745]	[19755]	PMC1974834_T465
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	cord	UBERON_EXT	[19759]	[19763]	PMC1974834_T568
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	blood	UBERON_EXT	[19764]	[19769]	PMC1974834_T569
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	sCAMs	PR_EXT	[19794]	[19799]	PMC1974834_T409
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	haemostatic	GO_BP_EXT	[19804]	[19815]	PMC1974834_T244
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	markers	CHEBI_EXT	[19816]	[19823]	PMC1974834_T118
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	markers	SO_EXT	[19816]	[19823]	PMC1974834_T466
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	cord	UBERON_EXT	[19827]	[19831]	PMC1974834_T570
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	blood	UBERON_EXT	[19832]	[19837]	PMC1974834_T571
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	tPAag	PR_EXT	[19895]	[19900]	PMC1974834_T410
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	pregnancies	GO_BP_EXT	[20259]	[20270]	PMC1974834_T245
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	antiatherogenic	CHEBI_EXT	[20297]	[20312]	PMC1974834_T119
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	sCAMs	PR_EXT	[20348]	[20353]	PMC1974834_T411
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	CRP	PR_EXT	[20355]	[20358]	PMC1974834_T412
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	haemostatic	GO_BP_EXT	[20363]	[20374]	PMC1974834_T246
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	PAI-1	PR_EXT	[20387]	[20392]	PMC1974834_T413
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	PAI-2	PR_EXT	[20394]	[20399]	PMC1974834_T414
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	tPAag	PR_EXT	[20401]	[20406]	PMC1974834_T415
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	vWF	PR_EXT	[20411]	[20414]	PMC1974834_T416
PMC1974834	PMC1974834_99	[20469]	[20661]	['Moreover, no differences were found between the groups in concentrations of the fetal blood variables measured other than a tendency to lower concentrations of tPAag in the intervention group.']	blood	UBERON_EXT	[20555]	[20560]	PMC1974834_T572
PMC1974834	PMC1974834_99	[20469]	[20661]	['Moreover, no differences were found between the groups in concentrations of the fetal blood variables measured other than a tendency to lower concentrations of tPAag in the intervention group.']	tPAag	PR_EXT	[20629]	[20634]	PMC1974834_T417
PMC1974834	PMC1974834_100	[20662]	[20840]	['Thus, the previously reported preventive effect of the current dietary intervention on preterm delivery is not likely to involve modification of systemic inflammatory biomarkers.']	delivery	GO_BP_EXT	[20757]	[20765]	PMC1974834_T247
PMC1974834	PMC1974834_100	[20662]	[20840]	['Thus, the previously reported preventive effect of the current dietary intervention on preterm delivery is not likely to involve modification of systemic inflammatory biomarkers.']	inflammatory	GO_BP_EXT	[20816]	[20828]	PMC1974834_T248
PMC1974834	PMC1974834_100	[20662]	[20840]	['Thus, the previously reported preventive effect of the current dietary intervention on preterm delivery is not likely to involve modification of systemic inflammatory biomarkers.']	biomarkers	CHEBI_EXT	[20829]	[20839]	PMC1974834_T120
PMC1974834	PMC1974834_100	[20662]	[20840]	['Thus, the previously reported preventive effect of the current dietary intervention on preterm delivery is not likely to involve modification of systemic inflammatory biomarkers.']	biomarkers	CHEBI_EXT	[20829]	[20839]	PMC1974834_T467
PMC1974834	PMC1974834_101	[20842]	[21068]	['Caption (FIG): FIGURE 4\n\nTrial profile.9\nTo our knowledge, the effect of a dietary intervention on markers of endothelial activation and inflammation has not been studied previously in women of fertile age or during pregnancy.']	markers	CHEBI_EXT	[20941]	[20948]	PMC1974834_T121
PMC1974834	PMC1974834_101	[20842]	[21068]	['Caption (FIG): FIGURE 4\n\nTrial profile.9\nTo our knowledge, the effect of a dietary intervention on markers of endothelial activation and inflammation has not been studied previously in women of fertile age or during pregnancy.']	endothelial	UBERON_EXT	[20952]	[20963]	PMC1974834_T573
PMC1974834	PMC1974834_101	[20842]	[21068]	['Caption (FIG): FIGURE 4\n\nTrial profile.9\nTo our knowledge, the effect of a dietary intervention on markers of endothelial activation and inflammation has not been studied previously in women of fertile age or during pregnancy.']	endothelial activation	GO_BP_EXT	[20952]	[20974]	PMC1974834_T249
PMC1974834	PMC1974834_101	[20842]	[21068]	['Caption (FIG): FIGURE 4\n\nTrial profile.9\nTo our knowledge, the effect of a dietary intervention on markers of endothelial activation and inflammation has not been studied previously in women of fertile age or during pregnancy.']	inflammation	GO_BP_EXT	[20979]	[20991]	PMC1974834_T250
PMC1974834	PMC1974834_101	[20842]	[21068]	['Caption (FIG): FIGURE 4\n\nTrial profile.9\nTo our knowledge, the effect of a dietary intervention on markers of endothelial activation and inflammation has not been studied previously in women of fertile age or during pregnancy.']	women	NCBITAXON_EXT	[21027]	[21032]	PMC1974834_T339
PMC1974834	PMC1974834_101	[20842]	[21068]	['Caption (FIG): FIGURE 4\n\nTrial profile.9\nTo our knowledge, the effect of a dietary intervention on markers of endothelial activation and inflammation has not been studied previously in women of fertile age or during pregnancy.']	women	UBERON_EXT	[21027]	[21032]	PMC1974834_T574
PMC1974834	PMC1974834_101	[20842]	[21068]	['Caption (FIG): FIGURE 4\n\nTrial profile.9\nTo our knowledge, the effect of a dietary intervention on markers of endothelial activation and inflammation has not been studied previously in women of fertile age or during pregnancy.']	pregnancy	GO_BP_EXT	[21058]	[21067]	PMC1974834_T251
PMC1974834	PMC1974834_102	[21069]	[21319]	['The reported significant differences in dietary saturated and unsaturated fat intakes between the groups are supported by the observed difference in some serum fatty acid levels (myristic, eicosapentaenic) between the intervention and control groups.']	unsaturated	CHEBI_EXT	[21131]	[21142]	PMC1974834_T122
PMC1974834	PMC1974834_102	[21069]	[21319]	['The reported significant differences in dietary saturated and unsaturated fat intakes between the groups are supported by the observed difference in some serum fatty acid levels (myristic, eicosapentaenic) between the intervention and control groups.']	fat	CHEBI_EXT	[21143]	[21146]	PMC1974834_T123
PMC1974834	PMC1974834_102	[21069]	[21319]	['The reported significant differences in dietary saturated and unsaturated fat intakes between the groups are supported by the observed difference in some serum fatty acid levels (myristic, eicosapentaenic) between the intervention and control groups.']	fat	CHEBI_EXT	[21143]	[21146]	PMC1974834_T575
PMC1974834	PMC1974834_102	[21069]	[21319]	['The reported significant differences in dietary saturated and unsaturated fat intakes between the groups are supported by the observed difference in some serum fatty acid levels (myristic, eicosapentaenic) between the intervention and control groups.']	serum	UBERON_EXT	[21223]	[21228]	PMC1974834_T576
PMC1974834	PMC1974834_102	[21069]	[21319]	['The reported significant differences in dietary saturated and unsaturated fat intakes between the groups are supported by the observed difference in some serum fatty acid levels (myristic, eicosapentaenic) between the intervention and control groups.']	fatty	CHEBI_EXT	[21229]	[21234]	PMC1974834_T577
PMC1974834	PMC1974834_102	[21069]	[21319]	['The reported significant differences in dietary saturated and unsaturated fat intakes between the groups are supported by the observed difference in some serum fatty acid levels (myristic, eicosapentaenic) between the intervention and control groups.']	fatty acid	CHEBI_EXT	[21229]	[21239]	PMC1974834_T124
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	ICAM	GO_CC_EXT	[21476]	[21480]	PMC1974834_T302
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	ICAM	PR_EXT	[21476]	[21480]	PMC1974834_T418
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	tPAag	PR_EXT	[21485]	[21490]	PMC1974834_T419
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	men	NCBITAXON_EXT	[21531]	[21534]	PMC1974834_T340
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	men	UBERON_EXT	[21531]	[21534]	PMC1974834_T578
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	antiatherogenic	CHEBI_EXT	[21580]	[21595]	PMC1974834_T125
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	pregnancy	GO_BP_EXT	[21604]	[21613]	PMC1974834_T252
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	markers	CHEBI_EXT	[21617]	[21624]	PMC1974834_T126
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	endothelial	UBERON_EXT	[21628]	[21639]	PMC1974834_T579
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	endothelial activation	GO_BP_EXT	[21628]	[21650]	PMC1974834_T253
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	inflammation	GO_BP_EXT	[21655]	[21667]	PMC1974834_T254
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	pregnant	GO_BP_EXT	[21755]	[21763]	PMC1974834_T255
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	women	NCBITAXON_EXT	[21764]	[21769]	PMC1974834_T341
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	pregnancy	GO_BP_EXT	[21787]	[21796]	PMC1974834_T256
PMC1974834	PMC1974834_105	[21935]	[22145]	['reducing maternal and neonatal total cholesterol levels.9The major strength of the CARRDIP study, on the other hand, is that it is a randomised dietary intervention trial in pregnancy with a prospective design.']	neonatal	UBERON_EXT	[21957]	[21965]	PMC1974834_T580
PMC1974834	PMC1974834_105	[21935]	[22145]	['reducing maternal and neonatal total cholesterol levels.9The major strength of the CARRDIP study, on the other hand, is that it is a randomised dietary intervention trial in pregnancy with a prospective design.']	cholesterol	CHEBI_EXT	[21972]	[21983]	PMC1974834_T127
PMC1974834	PMC1974834_105	[21935]	[22145]	['reducing maternal and neonatal total cholesterol levels.9The major strength of the CARRDIP study, on the other hand, is that it is a randomised dietary intervention trial in pregnancy with a prospective design.']	pregnancy	GO_BP_EXT	[22109]	[22118]	PMC1974834_T257
PMC1974834	PMC1974834_106	[22146]	[22277]	['In addition, the different dietary intake between the groups was verified through characterisation of the serum fatty acid profile.']	serum	UBERON_EXT	[22252]	[22257]	PMC1974834_T581
PMC1974834	PMC1974834_106	[22146]	[22277]	['In addition, the different dietary intake between the groups was verified through characterisation of the serum fatty acid profile.']	fatty	CHEBI_EXT	[22258]	[22263]	PMC1974834_T582
PMC1974834	PMC1974834_106	[22146]	[22277]	['In addition, the different dietary intake between the groups was verified through characterisation of the serum fatty acid profile.']	fatty acid	CHEBI_EXT	[22258]	[22268]	PMC1974834_T128
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	low-density lipoprotein	CHEBI_EXT	[22305]	[22328]	PMC1974834_T129
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	low-density lipoprotein	CHEBI_EXT	[22305]	[22328]	PMC1974834_T303
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	low-density lipoprotein	PR_EXT	[22305]	[22328]	PMC1974834_T420
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	LDL	CHEBI_EXT	[22330]	[22333]	PMC1974834_T130
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	LDL	CHEBI_EXT	[22330]	[22333]	PMC1974834_T304
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	cholesterol	CHEBI_EXT	[22335]	[22346]	PMC1974834_T131
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	gestation	GO_BP_EXT	[22365]	[22374]	PMC1974834_T258
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	LDL	CHEBI_EXT	[22417]	[22420]	PMC1974834_T305
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	LDL cholesterol	CHEBI_EXT	[22417]	[22432]	PMC1974834_T132
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	CRP	CHEBI_EXT	[22501]	[22504]	PMC1974834_T133
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	CRP	PR_EXT	[22501]	[22504]	PMC1974834_T421
PMC1974834	PMC1974834_108	[22535]	[22817]	['It is, therefore, notable that the significant increase in all other systemic parameters of inflammation through the study period, in accordance with previous literature,12,15,20,22was not observed with regard to CRP concentrations, which remained essentially unchanged (Figure 2d).']	inflammation	GO_BP_EXT	[22627]	[22639]	PMC1974834_T259
PMC1974834	PMC1974834_108	[22535]	[22817]	['It is, therefore, notable that the significant increase in all other systemic parameters of inflammation through the study period, in accordance with previous literature,12,15,20,22was not observed with regard to CRP concentrations, which remained essentially unchanged (Figure 2d).']	CRP	CHEBI_EXT	[22748]	[22751]	PMC1974834_T134
PMC1974834	PMC1974834_108	[22535]	[22817]	['It is, therefore, notable that the significant increase in all other systemic parameters of inflammation through the study period, in accordance with previous literature,12,15,20,22was not observed with regard to CRP concentrations, which remained essentially unchanged (Figure 2d).']	CRP	PR_EXT	[22748]	[22751]	PMC1974834_T422
PMC1974834	PMC1974834_109	[22818]	[22914]	['We have not identified any previously published longitudinal studies of CRP levels in pregnancy.']	CRP	GO_MF_EXT	[22890]	[22893]	PMC1974834_T316
PMC1974834	PMC1974834_109	[22818]	[22914]	['We have not identified any previously published longitudinal studies of CRP levels in pregnancy.']	CRP	PR_EXT	[22890]	[22893]	PMC1974834_T423
PMC1974834	PMC1974834_109	[22818]	[22914]	['We have not identified any previously published longitudinal studies of CRP levels in pregnancy.']	pregnancy	GO_BP_EXT	[22904]	[22913]	PMC1974834_T260
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	CRP	CHEBI_EXT	[22915]	[22918]	PMC1974834_T135
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	CRP	GO_MF_EXT	[22915]	[22918]	PMC1974834_T317
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	CRP	PR_EXT	[22915]	[22918]	PMC1974834_T424
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	gestation	GO_BP_EXT	[22949]	[22958]	PMC1974834_T261
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	pregnancy	GO_BP_EXT	[22990]	[22999]	PMC1974834_T262
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	CRP	CHEBI_EXT	[23090]	[23093]	PMC1974834_T136
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	CRP	PR_EXT	[23090]	[23093]	PMC1974834_T425
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	CRP	PR_EXT	[23192]	[23195]	PMC1974834_T426
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	pregnancy	GO_BP_EXT	[23199]	[23208]	PMC1974834_T263
PMC1974834	PMC1974834_111	[23246]	[23383]	['In normal pregnancy, concentrations of most clotting factors are reported to increase,32and our results agree with previous observations.']	pregnancy	GO_BP_EXT	[23256]	[23265]	PMC1974834_T264
PMC1974834	PMC1974834_111	[23246]	[23383]	['In normal pregnancy, concentrations of most clotting factors are reported to increase,32and our results agree with previous observations.']	clotting	GO_BP_EXT	[23290]	[23298]	PMC1974834_T265
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	Fibrinolytic	GO_BP_EXT	[23384]	[23396]	PMC1974834_T266
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	tissue	UBERON_EXT	[23420]	[23426]	PMC1974834_T583
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	tissue plasminogen activator	PR_EXT	[23420]	[23448]	PMC1974834_T427
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	plasminogen activator	PR_EXT	[23505]	[23526]	PMC1974834_T428
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	inhibitors	CHEBI_EXT	[23527]	[23537]	PMC1974834_T137
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	PAI-1	PR_EXT	[23538]	[23543]	PMC1974834_T429
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	PAI-2	PR_EXT	[23548]	[23553]	PMC1974834_T430
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	tPAag	PR_EXT	[23599]	[23604]	PMC1974834_T431
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	vWF	PR_EXT	[23606]	[23609]	PMC1974834_T432
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	PAI-1	PR_EXT	[23611]	[23616]	PMC1974834_T433
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	PAI-2	PR_EXT	[23621]	[23626]	PMC1974834_T434
PMC1974834	PMC1974834_114	[23754]	[24022]	['This finding indicates that lowering total and LDL cholesterol concentrations in low-risk pregnancies by lowering dietary saturated fat9is not accompanied by changes in haemostatic variables, at least not within the range of LDL lowering achieved in the present study.']	LDL	CHEBI_EXT	[23801]	[23804]	PMC1974834_T306
PMC1974834	PMC1974834_114	[23754]	[24022]	['This finding indicates that lowering total and LDL cholesterol concentrations in low-risk pregnancies by lowering dietary saturated fat9is not accompanied by changes in haemostatic variables, at least not within the range of LDL lowering achieved in the present study.']	LDL cholesterol	CHEBI_EXT	[23801]	[23816]	PMC1974834_T138
PMC1974834	PMC1974834_114	[23754]	[24022]	['This finding indicates that lowering total and LDL cholesterol concentrations in low-risk pregnancies by lowering dietary saturated fat9is not accompanied by changes in haemostatic variables, at least not within the range of LDL lowering achieved in the present study.']	pregnancies	GO_BP_EXT	[23844]	[23855]	PMC1974834_T267
PMC1974834	PMC1974834_114	[23754]	[24022]	['This finding indicates that lowering total and LDL cholesterol concentrations in low-risk pregnancies by lowering dietary saturated fat9is not accompanied by changes in haemostatic variables, at least not within the range of LDL lowering achieved in the present study.']	saturated fat9is	CHEBI_EXT	[23876]	[23892]	PMC1974834_T139
PMC1974834	PMC1974834_114	[23754]	[24022]	['This finding indicates that lowering total and LDL cholesterol concentrations in low-risk pregnancies by lowering dietary saturated fat9is not accompanied by changes in haemostatic variables, at least not within the range of LDL lowering achieved in the present study.']	haemostatic	GO_BP_EXT	[23923]	[23934]	PMC1974834_T268
PMC1974834	PMC1974834_114	[23754]	[24022]	['This finding indicates that lowering total and LDL cholesterol concentrations in low-risk pregnancies by lowering dietary saturated fat9is not accompanied by changes in haemostatic variables, at least not within the range of LDL lowering achieved in the present study.']	LDL	CHEBI_EXT	[23979]	[23982]	PMC1974834_T140
PMC1974834	PMC1974834_114	[23754]	[24022]	['This finding indicates that lowering total and LDL cholesterol concentrations in low-risk pregnancies by lowering dietary saturated fat9is not accompanied by changes in haemostatic variables, at least not within the range of LDL lowering achieved in the present study.']	LDL	CHEBI_EXT	[23979]	[23982]	PMC1974834_T307
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	Inflammatory	GO_BP_EXT	[24023]	[24035]	PMC1974834_T269
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	uteroplacental unit	UBERON_EXT	[24091]	[24110]	PMC1974834_T584
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	inflammatory	GO_BP_EXT	[24153]	[24165]	PMC1974834_T270
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	delivery	GO_BP_EXT	[24216]	[24224]	PMC1974834_T271
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	physiological	GO_BP_EXT	[24266]	[24279]	PMC1974834_T272
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	uteroplacental spiral arteries	UBERON_EXT	[24316]	[24346]	PMC1974834_T585
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	delivery	GO_BP_EXT	[24382]	[24390]	PMC1974834_T273
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	lipid	CHEBI_EXT	[24462]	[24467]	PMC1974834_T141
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	inflammatory	GO_BP_EXT	[24483]	[24495]	PMC1974834_T274
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	ICAM-1	GO_CC_EXT	[24546]	[24552]	PMC1974834_T308
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	ICAM-1	PR_EXT	[24546]	[24552]	PMC1974834_T435
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	cervicovaginal fluid	UBERON_EXT	[24556]	[24576]	PMC1974834_T586
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	delivery	GO_BP_EXT	[24634]	[24642]	PMC1974834_T275
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	women	NCBITAXON_EXT	[24646]	[24651]	PMC1974834_T342
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	labour	GO_BP_EXT	[24677]	[24683]	PMC1974834_T276
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	blood	UBERON_EXT	[24738]	[24743]	PMC1974834_T587
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	inflammatory	GO_BP_EXT	[24775]	[24787]	PMC1974834_T277
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	markers	CHEBI_EXT	[24788]	[24795]	PMC1974834_T142
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	markers	SO_EXT	[24788]	[24795]	PMC1974834_T468
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	uteroplacental	UBERON_EXT	[24907]	[24921]	PMC1974834_T588
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	cervical	UBERON_EXT	[24925]	[24933]	PMC1974834_T589
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	inflammatory	GO_BP_EXT	[24934]	[24946]	PMC1974834_T278
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	response	GO_BP_EXT	[24947]	[24955]	PMC1974834_T279
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	leukocyte	CL_EXT	[24994]	[25003]	PMC1974834_T154
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	endothelial	CL_EXT	[25004]	[25015]	PMC1974834_T155
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	endothelial	UBERON_EXT	[25004]	[25015]	PMC1974834_T590
PMC1974834	PMC1974834_116	[25029]	[25165]	['Whether lowering of maternal LDL cholesterol is directly involved in initiating a local anti-inflammatory response remains a hypothesis.']	LDL	CHEBI_EXT	[25058]	[25061]	PMC1974834_T309
PMC1974834	PMC1974834_116	[25029]	[25165]	['Whether lowering of maternal LDL cholesterol is directly involved in initiating a local anti-inflammatory response remains a hypothesis.']	LDL cholesterol	CHEBI_EXT	[25058]	[25073]	PMC1974834_T143
PMC1974834	PMC1974834_116	[25029]	[25165]	['Whether lowering of maternal LDL cholesterol is directly involved in initiating a local anti-inflammatory response remains a hypothesis.']	inflammatory	GO_BP_EXT	[25122]	[25134]	PMC1974834_T280
PMC1974834	PMC1974834_116	[25029]	[25165]	['Whether lowering of maternal LDL cholesterol is directly involved in initiating a local anti-inflammatory response remains a hypothesis.']	response	GO_BP_EXT	[25135]	[25143]	PMC1974834_T281
PMC1974834	PMC1974834_117	[25166]	[25431]	['Another finding, which supports the notion of a possible local effect in the intervention group, is that we observed a tendency towards lower concentrations of fetal tPAag in cord blood of fetuses born to mothers in the intervention compared with the control group.']	tPAag	PR_EXT	[25332]	[25337]	PMC1974834_T436
PMC1974834	PMC1974834_117	[25166]	[25431]	['Another finding, which supports the notion of a possible local effect in the intervention group, is that we observed a tendency towards lower concentrations of fetal tPAag in cord blood of fetuses born to mothers in the intervention compared with the control group.']	cord	UBERON_EXT	[25341]	[25345]	PMC1974834_T591
PMC1974834	PMC1974834_117	[25166]	[25431]	['Another finding, which supports the notion of a possible local effect in the intervention group, is that we observed a tendency towards lower concentrations of fetal tPAag in cord blood of fetuses born to mothers in the intervention compared with the control group.']	blood	UBERON_EXT	[25346]	[25351]	PMC1974834_T592
PMC1974834	PMC1974834_117	[25166]	[25431]	['Another finding, which supports the notion of a possible local effect in the intervention group, is that we observed a tendency towards lower concentrations of fetal tPAag in cord blood of fetuses born to mothers in the intervention compared with the control group.']	fetuses	UBERON_EXT	[25355]	[25362]	PMC1974834_T593
PMC1974834	PMC1974834_117	[25166]	[25431]	['Another finding, which supports the notion of a possible local effect in the intervention group, is that we observed a tendency towards lower concentrations of fetal tPAag in cord blood of fetuses born to mothers in the intervention compared with the control group.']	born	GO_BP_EXT	[25363]	[25367]	PMC1974834_T282
PMC1974834	PMC1974834_118	[25432]	[25518]	['To our knowledge, cord blood tPAag concentrations are not described in the literature.']	cord	UBERON_EXT	[25450]	[25454]	PMC1974834_T594
PMC1974834	PMC1974834_118	[25432]	[25518]	['To our knowledge, cord blood tPAag concentrations are not described in the literature.']	blood	UBERON_EXT	[25455]	[25460]	PMC1974834_T595
PMC1974834	PMC1974834_118	[25432]	[25518]	['To our knowledge, cord blood tPAag concentrations are not described in the literature.']	tPAag	PR_EXT	[25461]	[25466]	PMC1974834_T437
PMC1974834	PMC1974834_119	[25519]	[25765]	['tPAag is regarded a marker of atherosclerotic activity and to be an independent marker of coronary heart disease.25,35The effect of the diet on concentrations of tPAag in fetal blood is in accordance with the intervention study of Hjerkinn et al.']	tPAag	PR_EXT	[25519]	[25524]	PMC1974834_T438
PMC1974834	PMC1974834_119	[25519]	[25765]	['tPAag is regarded a marker of atherosclerotic activity and to be an independent marker of coronary heart disease.25,35The effect of the diet on concentrations of tPAag in fetal blood is in accordance with the intervention study of Hjerkinn et al.']	marker	CHEBI_EXT	[25539]	[25545]	PMC1974834_T144
PMC1974834	PMC1974834_119	[25519]	[25765]	['tPAag is regarded a marker of atherosclerotic activity and to be an independent marker of coronary heart disease.25,35The effect of the diet on concentrations of tPAag in fetal blood is in accordance with the intervention study of Hjerkinn et al.']	marker	CHEBI_EXT	[25539]	[25545]	PMC1974834_T469
PMC1974834	PMC1974834_119	[25519]	[25765]	['tPAag is regarded a marker of atherosclerotic activity and to be an independent marker of coronary heart disease.25,35The effect of the diet on concentrations of tPAag in fetal blood is in accordance with the intervention study of Hjerkinn et al.']	marker	CHEBI_EXT	[25599]	[25605]	PMC1974834_T145
PMC1974834	PMC1974834_119	[25519]	[25765]	['tPAag is regarded a marker of atherosclerotic activity and to be an independent marker of coronary heart disease.25,35The effect of the diet on concentrations of tPAag in fetal blood is in accordance with the intervention study of Hjerkinn et al.']	coronary heart	UBERON_EXT	[25609]	[25623]	PMC1974834_T596
PMC1974834	PMC1974834_119	[25519]	[25765]	['tPAag is regarded a marker of atherosclerotic activity and to be an independent marker of coronary heart disease.25,35The effect of the diet on concentrations of tPAag in fetal blood is in accordance with the intervention study of Hjerkinn et al.']	tPAag	PR_EXT	[25681]	[25686]	PMC1974834_T439
PMC1974834	PMC1974834_119	[25519]	[25765]	['tPAag is regarded a marker of atherosclerotic activity and to be an independent marker of coronary heart disease.25,35The effect of the diet on concentrations of tPAag in fetal blood is in accordance with the intervention study of Hjerkinn et al.']	blood	UBERON_EXT	[25696]	[25701]	PMC1974834_T597
PMC1974834	PMC1974834_120	[25766]	[25960]	['29However, we suggest that future studies attempting to assess a possible local effect of the intervention diet should include power calculations for tPAag in cord blood as a primary hypothesis.']	tPAag	PR_EXT	[25916]	[25921]	PMC1974834_T440
PMC1974834	PMC1974834_120	[25766]	[25960]	['29However, we suggest that future studies attempting to assess a possible local effect of the intervention diet should include power calculations for tPAag in cord blood as a primary hypothesis.']	cord	UBERON_EXT	[25925]	[25929]	PMC1974834_T598
PMC1974834	PMC1974834_120	[25766]	[25960]	['29However, we suggest that future studies attempting to assess a possible local effect of the intervention diet should include power calculations for tPAag in cord blood as a primary hypothesis.']	blood	UBERON_EXT	[25930]	[25935]	PMC1974834_T599
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	antiatherogenic	CHEBI_EXT	[26001]	[26016]	PMC1974834_T146
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	pregnancy	GO_BP_EXT	[26029]	[26038]	PMC1974834_T283
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	biomarkers	CHEBI_EXT	[26042]	[26052]	PMC1974834_T147
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	biomarkers	CHEBI_EXT	[26042]	[26052]	PMC1974834_T470
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	endothelial	UBERON_EXT	[26056]	[26067]	PMC1974834_T600
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	endothelial activation	GO_BP_EXT	[26056]	[26078]	PMC1974834_T284
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	inflammation	GO_BP_EXT	[26080]	[26092]	PMC1974834_T285
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	haemostasis	GO_BP_EXT	[26097]	[26108]	PMC1974834_T286
PMC1974834	PMC1974834_122	[26110]	[26192]	['All biomarkers increased during the study period except for CRP, which was stable.']	biomarkers	CHEBI_EXT	[26114]	[26124]	PMC1974834_T148
PMC1974834	PMC1974834_122	[26110]	[26192]	['All biomarkers increased during the study period except for CRP, which was stable.']	biomarkers	CHEBI_EXT	[26114]	[26124]	PMC1974834_T471
PMC1974834	PMC1974834_122	[26110]	[26192]	['All biomarkers increased during the study period except for CRP, which was stable.']	CRP	PR_EXT	[26170]	[26173]	PMC1974834_T441
PMC1974834	PMC1974834_123	[26193]	[26398]	['Thus, the previously reported effects of the diet during pregnancy on maternal lipid profile and risk of preterm delivery do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	pregnancy	GO_BP_EXT	[26250]	[26259]	PMC1974834_T287
PMC1974834	PMC1974834_123	[26193]	[26398]	['Thus, the previously reported effects of the diet during pregnancy on maternal lipid profile and risk of preterm delivery do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	lipid	CHEBI_EXT	[26272]	[26277]	PMC1974834_T149
PMC1974834	PMC1974834_123	[26193]	[26398]	['Thus, the previously reported effects of the diet during pregnancy on maternal lipid profile and risk of preterm delivery do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	delivery	GO_BP_EXT	[26306]	[26314]	PMC1974834_T288
PMC1974834	PMC1974834_123	[26193]	[26398]	['Thus, the previously reported effects of the diet during pregnancy on maternal lipid profile and risk of preterm delivery do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	inflammatory	GO_BP_EXT	[26362]	[26374]	PMC1974834_T289
PMC1974834	PMC1974834_123	[26193]	[26398]	['Thus, the previously reported effects of the diet during pregnancy on maternal lipid profile and risk of preterm delivery do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	responses	GO_BP_EXT	[26375]	[26384]	PMC1974834_T290
PMC1974834	PMC1974834_123	[26193]	[26398]	['Thus, the previously reported effects of the diet during pregnancy on maternal lipid profile and risk of preterm delivery do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	pregnancy	GO_BP_EXT	[26388]	[26397]	PMC1974834_T291
